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 Protein degradation is a major cause of skeletal muscle atrophy and is, at least in 
part, regulated at the level of gene transcription.  While obesity is characterized by 
impaired skeletal muscle carbohydrate and lipid metabolism, the effects of obesity on 
skeletal muscle protein metabolism, specifically protein degradation, have not been 
thoroughly examined.  Despite increased skeletal muscle mass, skeletal muscle of the 
severely obese overexpresses protein degradation genes, most notably, myostatin, 
which increases protein degradation by activating the transcription factor SMAD3, a 
mediator of transforming growth factor-β family signaling.  GOALS:  The aims of the 
present project were: 1) to determine how obesity affects skeletal muscle protein 
degradation mediated by the ubiquitin-proteasome system and the 
autophagic/lysosomal pathway, particularly at the level of gene expression and 2) to 
determine the role of SMAD3 in regulating gene transcription of MuRF-1, a gene 
involved in degradation of contractile proteins.  METHODS:  In order to accomplish 
these goals, primary human skeletal muscle (HSkMC) myotubes from lean and severely 
obese women were subjected to various atrophic stimuli (100nM dexamethasone or 
starved of serum and amino acids) and analyzed for gene expression and flux through 
the major protein degradation pathways.  Additionally, MuRF-1 promoter activity and 
RNA content were measured following co-expression of SMAD3 and FoxO3, a 
transcription factor known to induce MuRF-1 gene expression and cause muscle 
atrophy.  RESULTS:  Myotubes from the obese significantly overexpressed FoxO3, had 
a decreased rate of flux through the autophagic/lysosomal pathway, and increased 
proteasome capacity compared to lean.  Despite these differences, myotubes from lean 
and obese women atrophied at similar rates and displayed similar total protein 
degradation rates under basal and starved conditions.  Additionally, SMAD3 
overexpression was insufficient to induce MuRF-1 promoter activity or gene expression, 
but synergistically augmented FoxO3-induced MuRF-1 gene expression by increasing 
FoxO3 protein content and enhancing FoxO3 binding to the proximal MuRF-1 promoter 
region.  Furthermore, knockdown of SMAD3, via overexpression of a dominant-negative 
SMAD3, significantly attenuated FoxO3-induced MuRF-1 promoter activity.  Mutation of 
the SMAD Binding Element (SBE) within the MuRF-1 promoter region attenuated FoxO3 
binding to the FoxO Response Element (FRE), indicating SMAD3 is required for optimal 
FoxO3-induced MuRF-1 gene transcription.  CONCLUSIONS:  Skeletal muscle of the 
severely obese displays altered flux through the major protein degradation pathways, 
which may contribute to some of the metabolic impairments associated with obesity.  
However, severe obesity does not affect the total protein degradation rate or rate of 
muscle atrophy.  Furthermore, SMAD3 regulates MuRF-1 gene transcription through 
dual mechanisms:  1) increasing FoxO3 protein content and 2) increasing FoxO3 
binding within the proximal MuRF-1 promoter region.  Atrophic conditions that increase 
SMAD3 transcriptional activity may augment FoxO3-induced transcription of protein 
degradation genes and accelerate muscle atrophy.  Due to the observed overexpression 
of FoxO3, skeletal muscle of the severely obese may be more susceptible than that of 
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Chapter 1:  Global introduction and literature review 
Importance of Protein Degradation in Obesity: 
Severely decreased skeletal muscle mass, or muscle atrophy, affects over five 
million American adults, frequently presents secondary to other physiological (aging, 
fasting, or physical inactivity) or pathological (diabetes, heart failure, renal failure, 
respiratory disease, or cancer) conditions (68), and is a major cause of disability (47) 
and death (64, 71, 80, 95).  Despite a plethora of negative consequences, obesity is 
accompanied by increased skeletal muscle mass (27, 69), fiber diameter (28), and 
strength (53).  The molecular mechanism(s) underlying the observed hypertrophic 
phenotype in obesity is not well understood.  Furthermore, obesity exacerbates the 
negative effects of muscle atrophy; the combination of obesity and muscle atrophy 
increases risk of death to a greater extent than either condition independently (80).  
However, it is not known whether obesity per se increases the risk of developing muscle 
atrophy. 
Myocellular size, and therefore, skeletal muscle mass is dictated by the balance 
between the rates of protein synthesis and degradation (34).  Interestingly, the protein 
synthesis response to muscle atrophy is highly variable.  While many cachectic 
conditions are associated with decreased protein synthesis rates, it has previously been 
demonstrated that immobilization-induced atrophy occurs despite no change in protein 
synthesis rates (51).  However, protein degradation rate increases in all known models 
of muscle atrophy (13, 54, 82).  Obese mice (92), rats (74), and humans (23, 75) have a 
blunted hypertrophic response to muscle overload and feeding (27).  Therefore, it is 
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unlikely that the increased skeletal muscle mass observed in obesity is due to an 
increased rate of protein synthesis. 
The effects of obesity on protein degradation are poorly understood and remain 
controversial (48).  During fasting, the typical increase in proteolysis is blunted in obese 
humans (27, 73).  In contrast to these findings, Felig et al. (24) noted increased 
proteolysis in obesity as indicated by elevated plasma amino acids following an 
overnight fast.  Protein degradation at the whole-body level has been shown to be 
increased in obesity (39, 103).  Furthermore, diet-induced obesity increases expression 
of genes involved in protein degradation such as myostatin (42, 72).  Due to these 
discrepant findings, the effects of obesity on skeletal muscle protein degradation remain 
controversial. 
Protein degradation is mediated primarily by two pathways, the ubiquitin-
proteasome system (UPS) and the autophagic/lysosomal pathway (11, 107), and is 
essential for proper cellular function due to its role in eliminating damaged, misfolded or 
non-functional proteins and protein aggregates (66).  Accelerated protein degradation is 
a major cause of muscle atrophy (65). 
While the mechanisms controlling protein degradation are complex, it appears 
that numerous cachectic conditions share a common transcriptional response to 
increase protein degradation (13, 54, 82).  Using RNA microarray analysis, Lecker et al. 
(54) identified over 700 genes that were coordinately up- or down-regulated in at least 
two cachectic conditions and 133 that were coordinately regulated in four.  Interestingly, 
the transcriptional response to increase protein degradation appears to be largely driven 
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by only a few transcription factors, most notably FoxO (83, 93, 107) and SMAD3 (13, 
35, 56, 85).  Unfortunately, the cellular mechanisms that transcriptionally regulate flux 
through the major protein degradation pathways are incompletely understood, 
especially in obesity.  
 
Protein Degradation Pathways 
Protein degradation is mediated primarily by two pathways with functionally 
distinct roles:  the ubiquitin-proteasome system (UPS) and the autophagic/lysosomal 
pathway (84).  Together, these systems account for greater than 90% of protein 
degradation in mammalian cells and flux through both pathways is increased during 
muscle atrophy (11, 107).   
The ubiquitin-proteasome system (UPS) selectively degrades proteins in an ATP-
dependent manner (22, 70) and accounts for approximately 70% of total protein 
degradation in mammals (46).  The UPS consists of a multitude of highly regulated 
proteins that selectively tag and degrade damaged, misfolded, or unnecessary proteins 
(40, 104).  Ubiquitin ligases selectively attach polyubiquitin chains to target proteins 
which are recognized by the 19S cap of the proteasome.  Proteins are then unfolded 
and degraded by the 20S proteasome and constitutive amino acids and ubiquitin are 
recycled.  Flux through the UPS is dependent on protein ubiquitination as well as 
proteasome subunit composition and binding partners that alter catalytic activity of the 
proteasome (21, 76).   
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UPS-mediated protein degradation is regulated, at least in part, by gene 
transcription.  Gene expression of two muscle-specific ubiquitin ligases, Muscle-Specific 
RING Finger-1 (MuRF-1) and Atrogin-1, increases dramatically during muscle atrophy 
(54, 82).  These ubiquitin ligases have functionally distinct roles, but both are essential 
for muscle atrophy (8).  MuRF-1 functions primarily to target proteins of the thick 
filament for proteasome-mediated protein degradation (17, 18).  Atrogin-1 promotes 
degradation of eukaryotic translation initiation factor 3F (eIF3-F) (20), desmin and 
vimentin (58).  Additionally, Atrogin-1 putatively interacts with sarcomeric proteins (58).  
Transcription of Atrogin-1 and MuRF-1 is largely dependent on the transcription factor 
Forkhead box “O” (FoxO) (83, 93, 100).  During muscle atrophy, activating the PI3K/Akt 
pathway with IGF-1 results in a marked phosphorylation and cytosolic sequestration of 
FoxO1 and FoxO3, prevents upregulation of ubiquitin ligases, and preserves 
myocellular size (93).  Interestingly, MuRF-1 protein is higher in skeletal muscle of the 
obese (91), suggesting flux through this pathway may be disrupted in obesity. 
Like the UPS, the autophagic/lysosomal pathway is a major contributor to protein 
degradation (84).  It has recently been reported that, compared to the UPS, the 
autophagic/lysosomal pathway is upregulated to a greater extent during muscle atrophy 
(11, 107).  While the autophagic/lysosomal pathway can selectively degrade specific 
individual proteins, one major role of this pathway is degradation of organelles such as 
mitochondria (32).  Autophagosomes, double membraned vesicles form within the cell, 
recognize and engulf cellular material labeled for degradation.  Autophagosomes fuse 
with lysosomes to form autophagolysosomes and hydrolases contained within the 
lysosome non-selectively degrade proteins and organelles contained within the vesicle.  
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Impaired flux through the autophagic/lysosomal pathway has been shown to result in 
accumulation of damaged mitochondria and cause insulin resistance (106).  Therefore, 
it is possible that impaired autophagic/lysosomal flux may contribute to some of the 
metabolic perturbations associated with obesity.  
Importantly, the autophagic/lysosomal pathway, like the UPS, appears to be 
transcriptionally regulated.  Microtubule-associated protein 1 light chain 3β (LC3) 
associates with the inner membrane of autophagosomes and proteins labeled for 
degradation, thus committing these proteins to the autophagosome.  Due to its location 
within the autophagosome, LC3 is degraded by lysosome hydrolases within the 
autophagolysosome.  Therefore, transcription of LC3 must increase in order to replenish 
that consumed during protein degradation (98).  Therefore, in order to sustain 
autophagic/lysosomal-mediated protein degradation, transcription of LC3 must be 
increased.  Recently, Zhao et al. (107) demonstrated that FoxO3 overexpression 
increases gene expression of  LC3, Gabarapl-1, and Atg12 in muscle cells. 
 
Transcription factors regulating protein degradation 
Forkhead box type “O” (FoxO) coordinately regulates both UPS and 
autophagic/lysosomal-mediated protein degradation by increasing transcription of genes 
essential to these pathways.  Knockdown of FoxO (81, 87) is sufficient to preserve 
muscle mass during atrophic conditions indicating that FoxO-induced gene transcription 
is essential for increased protein degradation.  FoxO transcription factors recognize the 
consensus FoxO Response Element (FRE) (A/G)TAAA(T/C)A within the promoter 
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region to induce gene transcription (31, 83, 107).  Transcriptional activity of FoxO is 
inhibited by Akt-mediated phosphorylation and subsequent cytosolic sequestration (93).  
Insulin resistance, a common side-effect of severe obesity (77), decreases Akt activity 
and may thus increase FoxO-induced gene transcription and protein degradation.   
Despite its ability to induce muscle atrophy, FoxO alone may be insufficient to 
fully activate gene transcription.  Waddel et al. (100) recently demonstrated that the 
glucocorticoid receptor synergistically increases FoxO-induced transcription of MuRF-1.  
Furthermore, the close proximity of the glucocorticoid response element and the FRE 
within the MuRF-1 promoter region suggests that FoxO may form transcriptional 
complexes with complementary DNA-binding factors to augment FoxO-induced gene 
transcription.   In support of this, Ramaswamy et al. (79) demonstrated that a FoxO 
mutant lacking the DNA binding domain maintained the ability to induce gene 
transcription.   
SMAD3, a transcription factor that mediates Transforming Growth Factor-β (TGF-
β) family signaling, is a major determinant of protein degradation and plays a central 
role in the development of muscle atrophy (13).  SMAD3 is phosphorylated (activated) 
by ligand-receptor binding and associates with SMAD4 to gain nuclear access (61).  
SMAD3 directly interacts with DNA at the SMAD binding element (SBE, AGAC) to 
induce gene transcription (90).  While SMAD3 regulates gene expression of numerous 
genes, SMAD3-induced gene transcription is often relatively weak and non-specific 
unless accompanied by a complementary transcription factor (61).  Myostatin, a TGF-β 
family member, is elevated in numerous atrophic conditions such as heart failure, 
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glucocorticoid treatment, disuse, and cancer cachexia (14, 19, 29, 38, 55, 60, 102) and 
increases protein degradation in a SMAD3-dependent manner (56).  Overexpression of 
SMAD3 alone is sufficient to induce Atrogin-1 gene expression, increase protein 
degradation rate, and cause muscle atrophy (35, 85).  Interestingly, myostatin 
expression (1, 42, 59, 72) and SMAD3 activity (101) are increased in skeletal muscle of 
the severely obese, suggesting skeletal muscle of the obese may be more susceptible 
to muscle atrophy 
To date, the combined effects of FoxO and SMAD3 on protein degradation and 
muscle atrophy have not been explored.  These transcription factors are known to 
directly interact (88) and coordinately regulate gene expression (2, 33, 88).  Therefore, it 
is possible that FoxO3 and SMAD3 coordinately increase transcription of protein 
degradation genes during muscle atrophy. 
Conclusions 
Obesity is accompanied by both increased skeletal muscle mass and 
overexpression of genes involved in protein degradation.  Increased expression of 
protein degradation genes may put obese persons at increased risk of muscle atrophy 
during cachectic conditions such as heart failure, cancer, and type 2 diabetes.  To date, 
the effects of obesity on muscle mass and protein degradation have largely been 
ignored and the studies that have been performed have yielded conflicting results.  A 
common transcriptional response to muscle atrophy increases both UPS and 
autophagic/lysosomal-mediated protein degradation which is driven, in large part, by the 
transcription factor FoxO.  Decreased Akt activity in obesity-induced insulin resistance 
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may increase FoxO-induced gene transcription.  Additionally, increased TGF-β 
signaling, which is commonly observed in skeletal muscle of the obese, may augment 
FoxO-induced gene transcription and exacerbate muscle atrophy.  Therefore, the 
present project aimed to define the effects of obesity on the transcriptional regulation of 
skeletal muscle protein degradation.  Specifically, we hypothesized that: 
1)  Skeletal muscle of the obese overexpresses genes involved in the major 
protein degradation pathways. 
2) Protein degradation rate and flux through the major degradation pathways is 
higher in skeletal muscle of the obese. 
3) Skeletal muscle of the obese is more susceptible to muscle atrophy. 
4) SMAD3 augments FoxO-induced transcription of ubiquitin ligases. 
5) SMAD3 increases FoxO binding to the FRE within the promoter region of 
FoxO-inducible gene MuRF-1. 
 
Chapter 2:  Myotubes from lean and severely obese women degrade proteins at 
similar rates despite altered ubiquitin-proteasome system and 
autophagic/lysosomal pathway flux 
 
Abstract: 
Obesity is commonly accompanied by increased skeletal muscle mass, yet this tissue 
overexpresses many genes involved in protein degradation.  Despite evidence of 
increased whole-body protein turnover, the effects of obesity on skeletal muscle protein 
degradation have not been systematically explored.  The purpose of the present project 
was to determine how obesity affects protein degradation and transcription of atrophy-
related genes.  Methods:  Primary Human Skeletal Muscle (HSkMC) myotubes, a cell 
culture model that retains many characteristics of obesity, from 10 lean and 8 severely 
obese women were subjected to both hypertrophic (IGF-1) and atrophic 
(dexamethasone or serum and amino acid starvation) stimuli.  Gene expression 
patterns (RT-PCR), protein degradation rate, proteasome activity, and myotube area 
were measured at 24 h.  Results:  Gene expression patterns were similar between 
myotubes of lean and severely obese individuals with the exception of the transcription 
factor FoxO3, which was significantly higher in the severely obese.  Total protein 
degradation rate was similar between myotubes of the lean and severely obese.  
However, the rate of flux through the autophagic/lysosomal pathway was slower in 
myotubes from the obese.  Additionally, during starvation, the rate of flux through the 
ubiquitin-proteasome system (UPS) decreased in myotubes of the lean, but increased in 
myotubes of the obese, indicating a shift toward UPS-mediated protein degradation.  
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Furthermore, myotubes from the obese displayed elevated proteasome activity.  
Despite altered flux through the major protein degradation pathways, myotube area was 
similar between lean and obese under basal and starved conditions.  Conclusions:  
Despite increased gene expression of FoxO3, obesity does not affect the overall rate of 
muscle protein degradation but does alter flux through the major protein degradation 
pathways. Since the UPS and autophagic/lysosomal pathway preferentially degrade 
different cellular proteins and protein complexes, these findings suggest that the 




Obesity affects over one-third of American adults (25) and is a major risk factor 
for other chronic diseases and premature mortality (26).  Deficiencies in skeletal muscle 
carbohydrate and lipid metabolism underlie many of the metabolic abnormalities 
associated with obesity, such as type 2 diabetes (36). Furthermore, even though 
skeletal muscle mass is commonly increased in obese individuals (27, 69), skeletal 
muscle protein metabolism may also be impaired (48). However, this has not been 
thoroughly examined and remains controversial (48). Protein degradation is essential to 
proper cellular function.  Impaired protein degradation results in accumulation of 
misfolded, damaged, or otherwise non-functional proteins (66).  Alternatively, 
accelerated protein degradation is a major cause of muscle atrophy (65), which 
increases risk of disability and death (80).   
Protein degradation is mediated primarily by two pathways, the ubiquitin-
proteasome system (UPS) and the autophagic/lysosomal pathway.  The UPS accounts 
for the majority of basal cellular protein degradation (46).  Ubiquitin ligases target 
specific proteins for UPS-mediated degradation via polyubiquitination.  Flux through the 
UPS is dictated by proteasome assembly and activity as well as protein 
polyubiquitination and deubiquitination (76).  The autophagic/lysosomal pathway 
mediates degradation of the bulk of the remainder of cellular proteins, especially 
macromolecules and organelles such as mitochondria through macroautophagy (84).  
During this process, autophagosomes engulf cellular components, fuse with lysosomes, 
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and proteins are degraded by lysosomal hydrolases.  It is important to note that both 
pathways are upregulated during muscle atrophy (107).   
Interestingly, a common gene transcription profile has been observed in 
response to numerous stimuli that increase protein degradation rate (54, 82).  The 
transcription factors Forkhead Box O 1 and 3 (FoxO1) and (FoxO3) are upregulated in 
response to numerous atrophic stimuli (54).  These transcription factors regulate 
expression of the ubiquitin ligases Atrogin-1 and Muscle-specific RING Finger-1 (MuRF-
1), as well as genes involved in autophagic/lysosomal-mediated protein degradation, 
such as microtubule-associated protein 1 light chain 3β (LC3), GABA(A) receptor-
associated protein like-1 (Gabarapl-1), and autophagy-related 4B (ATG4B) (8, 83, 100, 
107).  Therefore, FoxO transcription factors appear to be master regulators of muscle 
atrophy by activating both the UPS and autophagic/lysosomal pathways. 
To date, studies regarding protein degradation in obesity have yielded 
controversial results.  Obesity is accompanied by increased strength (53), skeletal 
muscle mass (27, 69), and increased fiber diameter (28) compared to lean, suggesting 
the basal rate of protein degradation may be repressed.  Further, protein degradation 
may be less sensitive to atrophy signals, since during fasting the typical increase in 
proteolysis is blunted in obese humans (27, 73).  In contrast, others have noted that 
basal whole-body rates of protein degradation may be increased in obesity (24, 39, 
103), and diet-induced obesity increases expression of genes involved in protein 
degradation such as myostatin (42, 59, 72) and MuRF-1 (91).  Unfortunately, these in 
vivo studies are confounded by muscle overload, nutritional status, and elevated 
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circulating amino acids, factors that can alter protein metabolism and are inherently 
different between lean and obese subjects.  Therefore, given the prevalence of obesity, 
the roles of protein degradation in muscle mass regulation and cellular function, and the 
conflicting body of data regarding protein degradation in obesity, it is important to 
directly measure muscle protein degradation rates in obesity.   
Due to the well-described insulin resistance in vivo and in vitro (43) and elevated 
myostatin expression seen in skeletal muscle of the severely obese (1, 42, 72), we 
hypothesized that expression of protein degradation-related genes and rates of protein 
degradation would be higher basally in myotubes from the severely obese and that the 
myotubes from the obese would be more sensitive to signals known to alter protein 
degradation.  To this end, we measured protein degradation and gene expression 
profiles of cultured primary human skeletal muscle myotubes (HSkMC), a model that 
retains many characteristics of obesity in vitro (6, 10), in response to both hypertrophic 






Human subjects and muscle biopsies. 
Lean (BMI 18.5-26.0 kg/m2, n=10) and severely obese (BMI 39.0-57.3 kg/m2, 
n=8) subjects were recruited through ongoing studies on obesity at East Carolina 
University.  Muscle biopsy procedures were approved by East Carolina University 
Institutional Review Board and no personal identifiers were retained.  Blood samples 
were collected following an overnight fast and plasma glucose and insulin were 
measured.  Homeostatic model assessment (HOMA-IR), a marker of insulin resistance 
(62), was calculated (fasting plasma glucose x fasting plasma insulin/22.5).  Subject 
characteristics are presented in Table 2.1. 
 
Cell culture. 
Primary Human Skeletal Muscle (HSkMC) myoblasts were generated as 
previously described (5) by isolating satellite cells from muscle biopsies of the vastus 
lateralis of lean and severely obese female subjects.  Myoblasts were cultured in 
Dulbecco’s modified Eagle’s medium (DMEM, 1g glucose/L) supplemented with 10% 
fetal bovine serum, recombinant hEGF, dexamethasone, gentamycin, BSA, and fetuin 
(SkGM Singlequots, Lonza).  Upon reaching confluence, growth media was switched to 
low serum media (2% horse serum) supplemented with 3% BSA and 0.1% fetuin to 
induce differentiation into myotubes.  All experiments were performed on myotubes of 
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similar passage number (4-5) and days post-differentiation (6-8) to ensure these 
variables did not affect results.   
For experiments using pooled myotubes (UPS flux, autophagic/lysosomal flux, 
and proteasome capacity), myotubes were cultured individually until 50% confluent then 
seeded together in multiwell plates, allowed to adhere to the plate overnight, then 
switched to low serum media to induce differentiation.  Myoblasts were cultured 
independently prior to differentiation to eliminate effects of differing growth rates 
between myoblast cultures.  Pooled data was collected on two independent pools to 
confirm the accuracy of results.   
Myotubes were starved of serum and amino acids (cultured in HBSS) or treated 
with 100nM dexamethasone to induce protein degradation.  Additionally, myotubes 
were treated with 100nM IGF-1 to inhibit protein degradation.  100nM dexamethasone 
maximally induces protein degradation of C2C12 and L6 myotubes (63) and 100nM 
IGF-1 is sufficient to increase protein synthesis in HSkMC (Supporting information 2.1). 
 
Real-time PCR.   
 Total RNA was extracted from myotubes using TRIzol following 24 h of 
starvation, IGF-1 or dexamethasone treatment. RNA concentration and purity was 
assessed spectrophometrically (Ab260/280) using a NanoDrop UV-Vis spectrophometer 
(ThermoScientific, ND-1000).  Integrity of RNA was confirmed by agarose gel 
electrophoresis on a subset of individuals to ensure RNA was not degraded prior to 
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reverse transcription.  RNA was then reverse transcribed (Quanta Biosciences) and RT-
PCR performed (SYBR green chemistry, Applied Biosystems 7900HT) using standard 
methods as previously described (107). The expression of Large Ribosomal Protein 
(RPLPO), which was not different between lean and obese groups, was used as an 
endogenous control, and the fold expression of genes of interest was calculated using 
the relative standard curve method.  Standard curves were tested over eight orders of 
magnitude and amplification efficiency was near 100%.  Custom RT-PCR primers 
(Table 2.2) were generated using NCBI BLAST algorithms 
(http://blast.ncbi.nlm.nih.gov/Blast.cgi) and specificity confirmed by conventional PCR 
followed by agarose gel electrophoresis.   
Protein degradation rate.   
Degradation rate of long-lived proteins was determined as previously described 
(11).  Myotubes were radiolabeled with L-[3,5-3H] tyrosine (5-10µCi/ml, PerkinElmer Life 
Sciences) for 24 h.  Cells were washed and radioactivity chased for 2 h using 
differentiation media supplemented with 2mM L-tyrosine to allow degradation of short-
lived proteins and to limit re-incorporation of the radiolabel.  Fresh media was added, 
and media samples (3 or 4) were collected over time.  As we have previously reported, 
protein degradation rate (radioactivity release) is curvilinear over the course of 30 h 
(107).  Therefore, we assessed protein degradation over two time periods, either 0-5 h 
or 20-30 h.  The rates over these time periods were highly linear (R2>0.97) for all 
individuals.  At the end of the experiments, culture media was removed completely and 
myotubes were solubilized in 0.2N NaOH.  Radioactivity of cells and TCA-precipitated 
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media samples was measured using scintillation counting.  Total radioactivity was 
calculated as the sum of the residual radioactivity in the myotubes plus radioactivity of 
all time points.  Protein degradation rate was calculated from the regression line of 
serial samples for each individual and is given as a percentage of total [3H] tyrosine 
incorporation.   
Protein content. 
In a parallel experiment, myotubes were treated with IGF-1, dexamethasone, or 
starved for 24 h and cellular protein was collected.  Myotubes were washed twice with 
PBS and proteins collected with 300μl freshly made Radio-Immunoprecipitation Assay 
(RIPA) buffer containing 1% NP-40, 0.5% sodium deoxycholate, 0.1% SDS, and 
protease inhibitor cocktail (Roche Complete Mini).  Samples were vortexed continuously 
for 1min, rotated end-over-end for 30 min, then centrifuged at 12,000 x g for 10min and 
the pellet discarded.  Samples were stored at -80°C until processing and protein 
concentration (μg/ml) determined by bicinchoninic acid (BCA) assay (ThermoScientific). 
 
Relative flux through the UPS and autophagy pathways.   
In order to calculate relative flux through the UPS and autophagic/lysosomal 
pathways, we repeated the protein degradation assay described above in the presence 
of the highly specific proteasome inhibitor PS-341 (Bortezomib/Velcade) or the highly 
specific lysosome acidification inhibitor Concanamycin A as previously described (11, 
107) using pooled myotubes (3 individuals per pool).  During the two hour chase, 
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myotubes were pre-incubated with 1.0µM PS-341 and/or 0.1µM Concanamycin A for 1 
h and these inhibitors remained in the culture media for the duration of the experiment.  
Relative flux through the UPS and autophagy pathways was determined by subtracting 
the inhibitor-sensitive degradation rate from the basal degradation rate (Basal 
degradation rate – degradation rate with inhibitor = degradation rate attributable to 
inhibited pathway).  Differences between lean and obese myotubes were determined by 
subtracting the lean protein degradation rate from the corresponding value for the obese 
(Δ Degradation rate = degradation rateobese – degradation ratelean) 
 
Proteasome activity.   
Pooled myotubes (3 individuals per pool) were cultured in serum and amino acid 
free media for 24 h.  Purified proteasomes were collected as described by Kisselev and 
Goldberg (49).  Briefly, cell lysates were collected in buffer containing:  50mM Tris-HCl, 
pH 7.5, 250mM sucrose, 5mM MgCl2, 2mM ATP, 1mM DTT, 0.5mM EDTA and 0.025% 
digitonin to permeabilize the cell membrane.  Lysates were centrifuged at 20,000 x g for 
15 min to isolate the cytosolic fraction (supernatant) and chymotrypsin-like activity of the 
proteasome analyzed immediately.  The cytosolic fractions were plated in black 96 well 
microplates (30μl per well).  The fluorogenic amino acid substrate Suc-LLVY-amc 
(100µM final concentration, Bachem) was diluted in proteasome activity buffer and 
added to the microplate wells.  This substrate fluoresces upon chymotrypsin-like 
cleavage by the proteasome.  Fluorescence (excitation 380, emission 460) was 
measured using a microplate reader (Spectromax M4) over the course of 15 min.  
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Proteasome specificity for Suc-LLVY-amc was confirmed by treating cytosolic extracts 
with 100μM PS-341 (Bortezomib/Velcade).  Results were standardized to total protein 




Myotube area was quantified by analyzing the amount of myosin heavy chain 
covering the culture area (immunofluorescence) and total number of nuclei counted 
after staining with 4',6-diamidino-2-phenylindole (DAPI).  Myoblasts (~40% confluency) 
were plated in six well plates, grown to confluence, differentiated for 6-7d, and cultured 
in starvation media (HBSS) for 24 h.  Briefly, myotubes were washed with a 
cytoskeleton stabilizing buffer containing 80mM PIPES, 5mM EGTA, 1mM MgCl2, and 
40g/L PEG 35,000 as described by Trendelenurg et al (99).  Cross-linking was 
performed with 4% paraformaldehyde, and myotubes were permeabilized with 0.1% 
Triton X-100.  Non-specific binding was blocked with 10% rat serum.  Myotubes were 
then incubated with an antibody that detects all isoforms of myosin heavy chain 
(A4.1025, 1:100 dilution, Developmental Studies Hybridoma Bank) overnight at 4ºC.  
Immunofluorescence was achieved using a fluorogenic secondary antibody (AlexaFluor 
546, Invitrogen) and DAPI.  Myotubes were then imaged at 10x magnification using a 
fluorescent microscope (Leica DMI 4000B).  Antibody specificity was confirmed by the 
striated appearance of myotubes.  Wells (n=2 per condition) were divided into 10 
regions and a single image collected from each region (20 images/condition/individual).  
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Images were then processed using open-access software from NCBI (Image J, 
rsbweb.nih.gov/ij/) with a self-designed macro.  Images were split from RGB format to 
individual components (TRITC and DAPI), converted to threshold images, and analyzed 
for positive pixels (myosin heavy chain) or individual particles (nuclei count).  The total 
myosin heavy chain area was standardized to the number of nuclei to control for 
differences in seeding density.   
 
Statistical analysis. 
Statistical analysis for gene expression, protein degradation rate, protein content, 
and myotubes area data were determined by two-way repeated measures ANOVA with 
Sidak post-test comparisons.  Given our data mean and standard deviations for the 
protein degradation assay, a power analysis revealed that we would need 6-7 
observations to have an 80% chance of achieving a statistically significant difference 
with α=0.05.  Data from pooled myotubes (UPS flux, autophagic/lsysomal flux, and 
proteasome activity) were determined by two-way ANOVA with Sidak post-test 
comparisons.  Statistical analysis was performed using SPSS 19 and significance was 






Subjects were classified as lean or severely obese on the basis of body mass 
index (BMI, kg/m2).  By definition, severely obese (≥ 39.0 kg/m2) subjects displayed a 
higher BMI than their lean counterparts (≤ 26.0 kg/m2).  Additionally, the severely obese 
were significantly older than lean and displayed marked insulin resistance as assessed 
by homeostatic model assessment (HOMA-IR).       
 
Differential atrophy-related gene expression between lean and obese myotubes  
In order to determine how severe obesity affects the transcriptional response to 
muscle atrophy, we performed RT-PCR after 24 h of exposure to IGF-1, 
dexamethasone, or starvation.  Due to their roles in protein degradation, we analyzed 
genes involved in the UPS (FoxO3, Atrogin-1, and MuRF-1) and the 
autophagic/lysosomal pathway (LC3B, Gabarapl-1, and ATG4B).  These genes are 
known to be, at least in part, transcriptionally regulated (54, 107).  Furthermore, due to 
the well-documented increased myostatin expression (1, 42, 72) and TGF-β signaling in 
obesity (101), we analyzed genes involved in the myostatin/TGF-β signaling pathway.   
As shown in Figure 2.1A, starvation increased gene expression of MuRF-1 (lean: 
3.1 and obese: 4.5 fold) and Atrogin-1 (lean: 2.3, obese: 2.6 fold).  Interestingly, 
starvation increased FoxO3 gene expression in myotubes from the severely obese (1.4 
fold), but had no effect on myotubes from lean subjects.  Dexamethasone treatment 
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significantly increased gene expression of MuRF-1 (lean: 2.1 and obese: 2.5 fold) and 
FoxO3 (lean: 1.2 and obese: 1.5 fold), but had no effect on Atrogin-1. IGF-1 treatment 
significantly reduced gene expression of FoxO3 (lean: 0.8 and obese: 0.9 fold), but did 
not affect MuRF-1 or Atrogin-1 gene expression. 
Starvation significantly altered expression of genes involved in the 
autophagic/lysosomal pathway (Figure 2.1B).  Specifically, gene expression of 
Gabarapl-1, a gene essential for autophagosome formation, was significantly increased 
(lean: 1.3 and obese: 1.7 fold) in response to 24 h of starvation.  Gene expression of 
ATG4B, another regulator of autophagosome formation, was significantly reduced in 
response to 24 h of starvation (lean:  0.7 and obese:  0.9 fold).  LC3B is essential in 
committing proteins to the autophagosome membrane for degradation and, due to its 
location within the autophagosome, is degraded during autophagy (98).  Therefore, 
LC3B transcription must increase in order to sustain flux through the autophagy 
pathway.  Surprisingly, LC3B gene expression was unchanged after 24 h of starvation.  
In contrast to starvation, neither dexamethasone, nor IGF-1 had any effect on Gabarapl-
1, ATG4B, or LC3B gene expression. 
The TGF-β signaling pathway is known to negatively regulate muscle mass and 
signaling through this pathway is increased in severe obesity (101).  This is especially 
true for the muscle-specific cytokine, myostatin, and the transcription factors SMAD2 
and SMAD3 which mediate many of the effects of the TGF-β pathway.  As shown in 
Figure 2.1C, starvation significantly reduced gene expression of myostatin (lean: 0.6 
and obese: 0.8 fold) and SMAD3 (lean: 0.4 and obese: 0.6 fold), but had no effect on 
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SMAD2.  Similarly, dexamethasone significantly reduced myostatin (lean: 0.75 and 
obese: 0.83 fold) and SMAD3 (lean: 0.75 and obese: 0.80 fold), but not SMAD2, gene 
expression.  IGF-1 treatment did not significantly alter expression myostatin, SMAD2, 
nor SMAD3.  
As shown in Figure 2.1D, there was a significant group effect (p=0.039) for 
FoxO3 gene expression to be higher in the obese myotubes.  Under basal conditions, 
FoxO3 gene expression was 1.32 fold higher in obese myotubes.  While the direction of 
change in FoxO3 expression was similar between lean and obese in response to all 
experimental conditions, FoxO3 gene expression was higher in the obese in response 
to IGF-1 (1.46 fold), dexamethasone (1.54 fold) and starvation (1.84 fold).  However, the 
interaction between treatments and obesity failed to reach statistical significance 
(p=0.06).  No other genes tested were differentially expressed between myotubes of the 
lean and severely obese. 
 
Protein degradation rates are similar between myotubes of the lean and severely 
obese 
In order to determine whether protein degradation rates differ between skeletal 
muscle of the lean and severely obese, we directly measured protein degradation rates 
in primary HSkMC myotubes in response to 24 h of IGF-1, dexamethasone, or 
starvation.   
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Compared to lean, the rate of protein degradation tended to be reduced in 
myotubes from obese (1.45 vs. 1.31%/h) under basal conditions, although this 
difference failed to reach statistical significance (p=0.15, Figure 2.2A).  Likewise, basal 
protein synthesis was not different between myotubes of the lean and severely obese 
(Supporting information 2.2).  Starvation significantly increased protein degradation rate 
(~40%), however, there was no significant interaction between starvation and obesity.  
IGF-1 treatment decreased protein degradation rates by approximately 10% in lean and 
6% in severely obese, but this difference failed to reach statistical significance.  
Likewise, there was no significant effect of dexamethasone to increase protein 
degradation rate. 
As shown in Figure 2.2B, myotubes from the lean and severely obese contained 
similar amounts of total protein under basal conditions.  Following starvation, protein 
content of myotubes was significantly reduced to a similar extent (~20%) in myotubes 
from the lean and severely obese.  Likewise, IGF-1 significantly increased protein 
content (~6%) similarly in myotubes from the lean and severely obese.  Dexamethasone 
was insufficient to reduce protein content in either lean or severely obese.    
 
Differential flux through proteasome- and autophagy- mediated protein 
degradation 
Although total protein degradation rates were found to be similar, we next wanted 
to determine how obesity affects flux through the major protein degradation pathways, 
since these pathways preferentially target different proteins and/or organelles for 
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degradation (84).  In order to accomplish this, we pooled myotubes from three lean and 
three obese individuals and measured protein degradation rates in response to 
proteasome inhibition (1.0μM PS-341, Bortezomib), lysosome acidification inhibition 
(0.1μM concanamycin A), or combined proteasome and lysosome inhibition.  Inhibitor 
dosages were determined as the lowest dose effective to yield maximal inhibition during 
a dose-response experiment (Figure 2.3A).  
In order to determine the rate of flux through the UPS and autophagic/lysosomal 
pathways, we subtracted inhibitor-sensitive protein degradation rate from the vehicle-
treated total protein degradation rate (Figure 2.3B).  The rates of flux through each 
pathway are depicted in Figure 2.3C.  There was a significant group effect for myotubes 
of the severely obese to have decreased flux (basal -26%, starved -18%) through the 
autophagic/lysosomal pathway. Surprisingly, starvation reduced UPS flux by 19% in 
myotubes of the lean myotubes, but increased UPS flux by 4% in myotubes of the 
severely obese. This interaction was statistically significant, indicating a shift toward 
UPS-mediated protein degradation in myotubes of the severely obese during starvation.  
During starvation, flux through the autophagic/lysosomal pathway doubled in myotubes 
of the lean and severely obese.  The magnitude of the differences in total, proteasomal, 
and lysosomal degradation rates are depicted in Figure 2.3D.   
 
Proteasome activity is increased in obese myotubes 
We next examined how severe obesity affects proteasome activity to determine 
whether this may explain the altered UPS flux during starvation.  Therefore, we pooled 
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myotubes of three lean and of three obese individuals and subjected each pool to 
starvation for 24 h, then measured chymotrypsin-like activity of the purified proteasomes 
with the fluorogenic substrate Suc-LLVY-amc.  The proteasome inhibitor PS-341 
attenuated fluorescence in a dose-response manner (data not shown), indicating the 
specificity of this assay for proteasome activity. 
As shown in Figure 2.4, there was a significant group effect for chymotrypsin-like 
activity of the proteasome to be higher in myotubes of the obese than lean.  Starvation 
significantly increased proteasome activity in myotubes of the lean (30%) and severely 
obese (23%).  However, there was no significant interaction between obesity and 
starvation on proteasome capacity. 
 
Myotubes from the lean and severely obese atrophy to a similar extent in 
response to starvation 
It is well-known that contractile elements of the sarcomere are degraded in a 
proteasome-dependent manner (18).  Therefore, due to the altered UPS flux and 
proteasome capacity observed in severe obesity, we next sought to determine how 
obesity affects loss of myotube size during starvation.  Myotubes were subjected to 
starvation for 24 h and myotube area quantified by immunofluorescence of myosin 
heavy chain (Figure 2.5A).  Starvation was used as a model of atrophy due to the 
dramatic upregulation of protein degradation rate and loss of protein content (c.f. Figure 
2.2).  As shown in Figure 2.5, myotube area (2.5B), nuclei number (2.5C) and myotube 
area/nucleus (2.5D) were similar between lean and obese under basal conditions.  As 
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expected, there was a significant main effect for starvation to decrease myotube area 
(~30%, p<0.05).  Interestingly, there was also a significant main effect of starvation to 
reduce nuclei number (~15%), suggesting this treatment may also induce apoptosis, as 
has been described in mouse muscle myotubes (C2C12) (86). Despite the reduced 
number of nuclei following starvation, starvation significantly reduced myotube 
area/nucleus (~20%), demonstrating that loss of myotube size occurs to a greater 
extent than loss of nuclei number.  However, there was no significant interaction 
between obesity and starvation on muscle atrophy. Following 24 h of starvation, 
myotube area and myotube area/nucleus were similar between myotubes of the lean 





Contrary to our original hypothesis, we found no differences in absolute protein 
degradation rate between myotubes of the lean and severely obese, despite increased 
FoxO3 gene expression.  Importantly, flux through the major protein degradation 
pathways, is altered in myotubes from the severely obese.  To our knowledge, this is 
the first study to directly measure flux through the UPS and autophagic/lysosomal 
pathways of skeletal muscle from lean and severely obese humans.  Given the distinct 
roles of the UPS and autophagic/lysosomal pathways (84), the specific proteins 
degraded during muscle atrophy may be substantially different between lean and 
severely obese skeletal muscle.   
HSkMC myotubes are an excellent model with which to study protein metabolism 
in obesity. First, since the myoblasts are purified and passaged in culture for many 
weeks (5), cells from lean and obese individuals are subject to the same extracellular 
conditions. Therefore, the differences we observe are specific to skeletal muscle of lean 
and severely obese and not due to different cell types, circulating factors, or physical 
activity. Second, HSkMC myotubes, purified and passaged exactly as we have done 
here, retain many metabolic characteristics observed in vivo (43). For instance, HSkMC 
derived from severely obese individuals are insulin resistant (6) and have impaired fatty 
acid oxidation (10).  Therefore, phenotypic differences in myotubes are likely to be 
present in vivo. 
Compared to lean, both the absolute rate of flux through the 
autophagic/lysosomal pathway and its relative contribution to total protein degradation 
are decreased in myotubes from the extremely obese.  The autophagic/lysosomal 
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pathway, but not the UPS, is responsible for the degradation of entire organelles, such 
as mitochondria.  It has previously been observed that obesity is accompanied by 
impaired mitochondrial function (9).  It is possible that decreased flux through the 
autophagic/lysosomal pathway may slow degradation of damaged or non-functional 
mitochondria within obese skeletal muscle.  In support of this, Wu et al. (106) recently 
described impaired mitochondrial respiration and insulin resistance in mice with skeletal 
muscle deletion of Autoghapy-related gene 7 (Atg-7).  Therefore, decreased 
autophagic/lysosomal pathway flux may represent not only impaired protein metabolism 
in obese skeletal muscle, but may also contribute to impaired carbohydrate and lipid 
metabolism. Future research should aim to discover the mechanistic causes and clinical 
significance of differential flux through the protein degradation pathways in obesity.   
Additionally, we found that UPS flux is differentially regulated between lean and 
obese myotubes in response to starvation.  Compared to lean, UPS flux was 13% lower 
in myotubes of the severely obese under basal conditions and 12% higher in response 
to starvation.  The increased UPS flux in response to starvation indicates a shift toward 
UPS-mediated protein degradation in myotubes of the severely obese.  It is well-known 
that the UPS mediates degradation of specific proteins, including contractile proteins 
(18).  Despite elevated UPS flux, starved myotubes of the severely obese degrade 
proteins and lose myotube area at similar rates as those of lean individuals (c,f. Figure 
2.2 and 2.5).  However, it is possible that this shift may result in increased degradation 
of specific contractile proteins (18) and therefore contribute to lower specific force 
generation in muscles of the obese (44).  Future research should examine whether 
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there is a preferential loss of specific contractile proteins in skeletal muscle of the 
severely obese during muscle atrophy. 
UPS flux is determined by catabolic activity of the proteasome and protein 
polyubiquitination and deubiquitination (3, 104, 105).  We determined that maximal 
proteasome activity is significantly greater in myotubes from obese individuals (c.f. 
Figure 2.4).  Recently, several proteins have been identified that bind to, and modify, 
catabolic activity of the proteasome (21, 76).  Therefore, it is possible that proteasome 
binding partners are differentially expressed in obese skeletal muscle.  However, we 
noted that starvation increased proteasome activity to a similar extent in both lean and 
obese myotubes.  Therefore, it is unlikely that proteasome activity alone can explain the 
elevated UPS flux seen in myotubes of the obese in response to starvation.  Gene 
expression of two major E3 ubiquitin ligases essential for muscle protein degradation, 
Atrogin-1 and MuRF-1, were similarly expressed in myotubes from the lean and 
severely obese under basal and starved conditions.  However, it is possible that 
increased expression of other E3 ligases or increased ubiquitin ligase activity may 
explain the increased UPS flux in myotubes of the obese in response to starvation.  
Alternatively, decreased expression of deubiquitinating enzymes during starvation may 
increase UPS flux in myotubes of the obese.  To date, few studies have examined the 
role of deubiquitinating enzymes during muscle atrophy, although several 
deubiquitinating enzymes are upregulated during muscle atrophy (3, 105).   
Protein degradation responses are, at least in part, regulated at the level of gene 
transcription (25, 33).  We noted a similar pattern of gene expression between lean and 
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obese myotubes under basal, IGF-1, dexamethasone, or starved conditions; all genes 
analyzed displayed a similar expression level between lean and obese myotubes with 
the exception of FoxO3, which was higher in the obese.  FoxO3 is known to activate 
muscle atrophy through upregulation of genes involved in both the UPS and the 
autophagic/lysosomal pathway (107).  Interestingly, despite elevated FoxO3 gene 
expression, we found similar expression patterns of the FoxO3-inducible genes Atrogin-
1, MuRF-1, LC3B, and Gabarapl-1 between lean and obese myotubes.  This suggests 
obese skeletal muscle may be resistant to the atrophic effects of FoxO3. Transcriptional 
activity of FoxO3 is, in large part, dictated by Akt-mediated phosphorylation and 
cytosolic sequestration (93).  Sishi et al. (91) determined FoxO phosphorylation is 
decreased in skeletal muscle of obese, pre-diabetic rats.  Due to whole-body insulin 
resistance observed in our severely obese subjects (Table 2.1), it is reasonable to 
expect that FoxO3 phosphorylation may be reduced in these myotubes and therefore 
inhibit FoxO3-induced gene expression.   
Taken together, our data indicate that skeletal muscle of the lean and severely 
obese atrophy at similar rates, but through different mechanisms.  Specifically, skeletal 
muscle of the severely obese has decreased flux through the autophagic/lysosomal 
pathway under basal and starved conditions.  Additionally, during starvation, skeletal 
muscle of the severely obese experiences a relative shift toward UPS-mediated protein 
degradation.  Despite differential flux through the UPS and autophagic/lysosomal 
pathways, total loss of myocellular size and total protein degradation rates are similar 
between skeletal muscle of the lean and severely obese in response to starvation.  
Myotubes of the severely obese overexpress FoxO3, a transcription factor largely 
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responsible for increasing transcription of genes involved in both the UPS and the 
autophagic/lysosomal pathway, however, gene expression patterns of FoxO3-inducible 
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Lean 10 24.2 ± 1.5 22.9 ± 0.8 85.2 ± 2.6   9.3 ± 1.1 1.65 ± 0.2 
Obese 8 34.1 ± 3.3* 46.9 ± 2.1* 93.7 ± 2.9 18.2 ± 2.2* 4.27 ± 0.6* 
 
Table 2.1.  Subject characteristics. Data are presented as mean ± SEM.  BMI = body mass index 
(kg/m
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Figure 2.1.  IGF-1, dexamethasone, and starvation alter atrophy-related gene expression in 
myotubes of lean and severely obese.    Myotubes were treated for 24 h, RNA was collected, and RT-
PCR was performed.  A:  Genes involved in the ubiquitin-proteasome system (UPS).  B:  Genes involved 
in the autophagic/lysosomal pathway.  C:  Genes involved in Transforming Growth Factor-β (TGF-β) 
signaling.  D:  FoxO3 gene expression of obese myotubes expressed as fold relative to lean.  Fold 
changes were calculated using the relative standard curve method.  Data are presented as mean ± SEM. 
* Significant main effect of treatment (p<0.05). 





Figure 2.2. Protein degradation rates of lean and obese myotubes respond similarly to atrophic 
and hypertrophic stimuli.  A: Protein degradation rate:  myotubes were labeled with 
3
H-tyrosine for 24hr 
then subjected to starvation, dexamethasone, or IGF-1.  Protein degradation rate was calculated by the 
amount of 
3
H in media samples collected over the course of 5hr (starved) or 20-30hr (IGF-1, 
dexamethasone).  Each data point is the mean of four replicates.  B: Protein content:  myotubes were 
subjected to treatments for 24 h and protein content determined by BCA assay. Data are presented as 
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Figure 2.3.  Flux through the ubiquitin-proteasome system and autophagic/lysosomal pathway is 
altered in myotubes from the severely obese.  Pooled myotubes (three individuals per group) were 
treated with the proteasome inhibitor PS-341 and/or the lysosome inhibitor Concanamycin A, incubated in 
serum and amino acid free media, and protein degradation rates determine by 
3
H-tyrosine release.  A-B:  
Dose-response curves for inhibitors used.  C:  Protein degradation rates in response to inhibitors.  D:  
Inhibitor-sensitive proteolysis was determined by subtracting the degradation rate in the presence of 
inhibitors from vehicle-treated controls.  E:  Differences in protein degradation rates were determined by 
subtracting values of lean from obese (Δ Degradation rate = degradation rateobese – degradation ratelean).  
Data are presented as mean ± SEM. * Significant main effect of treatment (p<0.05).  † Significant main 
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Figure 2.4.  Proteasome activity is increased in myotubes from the severely obese. Chymotrypsin-
like activity was assessed by the fluorogenic substrate Suc-LLVY-amc.  ‡ Significant main effect (basal vs 
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Figure 2.5.  Myotubes from lean and severely obese atrophy at similar rates.  A:  Representative 
two-colored fluorescent images stained for both myosin heavy chain and nuclei (Overlay).  Images were 
split from RGB format to individual components and converted to threshold images representing Myosin 
Heavy Chain and Nuclei, B:  Myotube area (μm
2
).  C:  Number of nuclei.  D:  Myotube area per nucleus 
(μm
2
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Supporting information 2.1:  100nM IGF-1 increases rate of protein synthesis in HSkMC myotubes.  
Myotubes were treated with vehicle (HCl), 10nM IGF-1, or 100nM IGF-1 for 24 h then radiolabeled with 
5μCi/ml 
3
H-tyrosine for 2 h, cellular proteins precipitated by 10% TCA, washed in 95% ethanol, and 
solubilized in 0.2N NaOH.  TCA precipitable radioactivity was determined by scintillation counting and 
normalized to total protein (assessed by bicinchoninic acid assay). Data are presented as mean ± SEM. 













Supporting information 2.2:  Basal protein synthesis rate is similar between myotubes of lean and 
severely obese women.  Pooled myotubes (four per group) were radiolabeled with 5μCi/ml 
3
H-tyrosine 
for 2 h, cellular proteins precipitated by 10% TCA, washed in 95% ethanol, and solubilized in 0.2N NaOH.  
TCA precipitable radioactivity was determined by scintillation counting and normalized to total protein 
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During muscle atrophy, Muscle-specific RING Finger-1 (MuRF-1) targets muscle 
contractile proteins for rapid degradation.  The transcription factors SMAD3 and FoxO 
independently increase transcription of protein degradation genes and cause muscle 
atrophy.  However, it is not known whether these transcription factors coordinately 
regulate transcription of ubiquitin ligases.  It is possible that these transcription factors 
synergistically increase transcription of ubiquitin ligases during muscle atrophy.  The 
purpose of the current project was to determine the additive effects of these 
transcription factors on ubiquitin ligase gene transcription.  Methods: C2C12 myotubes 
were infected with adenoviruses encoding for SMAD3 and/or FoxO3 and gene 
expression of Atrogin-1 and MuRF-1 measured by RT-PCR.  Human embryonic kidney 
(HEK293a) cells were co-transfected with plasmid DNA encoding MuRF-1 luciferase 
reporters (wt or SBE-mutant), FoxO1, FoxO3, and/or SMAD3.  Results: 
Overexpression of FoxO3 increased gene expression of Atrogin-1 and MuRF-1 and this 
effect was synergistically increased by co-expression of SMAD3.  Co-expression of 
FoxO3 and SMAD3 synergistically increased FoxO3 and SMAD3 DNA interactions and 
MuRF-1 promoter activity.  Mutagenesis of the SMAD binding elements eliminated 
SMAD3-DNA interactions and significantly attenuated FoxO3-DNA interactions and 
FoxO-induced MuRF-1 promoter activity, suggesting SMAD3 is essential for optimal 
FoxO-induced transcription of MuRF-1.  SMAD3 overexpression increased FoxO3 
protein content in a dose-dependent manner, but had no effect on FoxO1 or FoxO3 
45 
mRNA.  Co-expression of FoxO3 and SMAD3 synergistically increased FoxO-
dependent gene transcription as indicated by FRE-driven luciferase activity.  
Conclusions: SMAD3 synergistically increases FoxO-induced transcription of the 
ubiquitin ligases Atrogin-1 and MuRF-1.  SMAD3 appears to be essential for optimal 
FoxO-induced MuRF-1 gene transcription by increasing FoxO binding to the proximal 
promoter region.  Additionally, SMAD3 overexpression increases protein content and 
transcriptional activity of FoxO, possibly by inhibiting degradation of FoxO protein.  We 
conclude that SMAD3 regulates gene transcription of ubiquitin ligases through a dual 
effect on FoxO:  1) increasing FoxO protein content and transcriptional activity and 2) 





Skeletal muscle mass is dictated by the balance between protein synthesis and 
degradation rates (34).  Severe loss of muscle mass, or muscle atrophy, is 
characterized by an increased protein degradation rate.  This is especially true for 
ubiquitin proteasome system (UPS)-mediated protein degradation (46).  Numerous 
forms of muscle atrophy activate a common transcriptional program to induce 
expression of genes involved in protein degradation, including the ubiquitin ligases 
Atrogin-1 and  Muscle-specific RING Finger-1 (MuRF-1) (54, 78, 82).  Atrogin-1 
promotes degradation of eukaryotic translation initiation factor 3F (eIF3-F) (20) as well 
as desmin and vemintin (58).  During muscle atrophy, MuRF-1 targets contractile 
proteins of the thick filament for degradation (18), thereby contributing to both 
decreased skeletal muscle mass and decreased muscle force development.  
Furthermore, these ubiquitin ligases are essential for muscle atrophy (8) and are known 
to be, at least in part, transcriptionally regulated (54).  Unfortunately, the cellular 
mechanisms regulating transcription of Atrogin-1 and MuRF-1 are incompletely 
understood.   
Atrogin-1 and MuRF-1 gene expression is clearly regulated, at least in part, by 
the transcription factor Forkhead box type O (FoxO) (81, 87, 100).  FoxO1 and 3 are 
sufficient to induce protein degradation (83, 107), Atrogin-1 (83) and MuRF-1 gene 
expression (87, 100), and ultimately, muscle atrophy.  FoxO recognizes the FoxO 
Response Element (FRE, (A/G)TAAA(T/C)A) within the promoter region to induce 
transcription of Atrogin-1 and MuRF-1 (83, 100).  Interestingly, the synthetic 
glucocorticoid dexamethasone synergistically increases FoxO-induced MuRF-1 
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promoter activity (100), suggesting that FoxO may require DNA binding partners to fully 
activate the MuRF-1 promoter region. 
One potential FoxO DNA binding partner is SMAD3, a transcription factor 
activated by the Transforming Growth Factor-β (TGF-β) pathway.  A recent meta-
analysis of human and rodent microarray studies implicated the TGF-β pathway as the 
core pathway and SMAD3 as a major signaling node for general muscle atrophy (13).  
Gene expression of Atrogin-1 and MuRF-1 is increased following administration of the 
TGF-β family member myostatin in vitro (56, 57).  Overexpression of SMAD3 induces 
muscle atrophy and Atrogin-1 gene expression, but is insufficient to induce MuRF-1 
gene transcription in vitro (35) or in vivo (85).  Therefore the direct role of SMAD3 
transcriptional regulation of ubiquitin ligases is somewhat controversial.  SMAD3 
regulates FoxO activity by inhibiting Akt-mediated phosphorylation (and cytosolic 
sequestration) of FoxO (4, 67, 99).  FoxO and SMAD transcription factors have 
previously been shown to physically associate and synergistically regulate the cyclin-
dependent kinase inhibitor p21Cip1 gene expression (88).  Furthermore, of 115 genes 
regulated by TGF-β in keratinocytes, 11 require FoxO as a DNA binding partner (33).  
Therefore, it is possible that SMAD3 may modulate FoxO-induced transcription of 
muscle-specific ubiquitin ligases.   
Both SMAD3 and FoxO transcription factors are known to be major regulators of 
the transcriptional program that induces muscle atrophy (37).  The effects of these 
transcription factors on atrophy have largely been studied independently; the effects of 
the interaction between these transcription factors have not been well characterized.  
The purpose of the present study was to determine how FoxO- and SMAD3- DNA 
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interactions coordinately regulate gene expression of muscle-specific ubiquitin ligases.  
Since it has previously been reported that SMAD3 and FoxO coordinately regulate 
several genes, we hypothesized that SMAD3 functions to augment FoxO-dependent 





Primary human skeletal muscle myoblasts (HSkMC) were generated as 
previously described (5) by isolating satellite cells from muscle biopsies of the vastus 
lateralis from four female subjects.  Myoblasts were pooled and cultured together in 
Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10 % fetal bovine 
serum, rhEGF, dexamethasone, gentamycin, BSA, and fetuin (SkGM Singlequots, 
Lonza).  Upon reaching confluence, growth media was switched to low serum media (2 
% horse serum) supplemented with 3 % BSA and 0.1 % fetuin to induce differentiation 
into myotubes.  Experiments were performed on day 6 of differentiation using two 
independent pools. 
Human Embryonic Kidney (HEK, 293a) cells were cultured in DMEM 
supplemented with 10 % fetal bovine serum and 1 % penicillin/streptomycin.  For all 
experiments, cells were seeded into six well plates at a density of 2.5 x 105 cells per 
well and allowed to adhere to the plate overnight.   
Mouse skeletal muscle myoblasts (C2C12) were cultured in DMEM 
supplemented with 10 % fetal bovine serum and 1 % penicillin/streptomycin and 
maintained at sub-confluent density prior to differentiation.  For all experiments, 
myoblasts were seeded into six well plates at a density of 2.5x105 cells per well and 
allowed to adhere to the plate overnight.  Growth media was switched to low serum 
media (2 % horse serum) to induce differentiation into myotubes.  Experiments were 
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performed on day 5 of differentiation. All cell cultures were maintained at 37°C and 5 % 
CO2 and media was changed every 48 h.   
 
Protein Degradation Rate: 
Protein degradation rates were determined by release of a radiolabeled amino 
acid as previously described (11).  Terminally differentiated myotubes were radiolabeled 
with L-[3,5-3H] tyrosine (5 µCi/ml, PerkinElmer Life Sciences) for 24 h.  Cells were 
thoroughly washed and radioactivity chased for 2 h using differentiation media 
supplemented with 2 mM L-tyrosine to allow degradation of short-lived proteins and to 
limit re-incorporation of the radiolabel.  Myotubes were then subjected to atrophic 
stimuli.  For HSkMC experiments, myotubes were incubated in media lacking serum 
(DMEM only), lacking amino acids (HBSS+2 %HS), or lacking both serum and amino 
acids (HBSS only).  Four serial media samples were collected over the course of 5 h.  
At the end of the experiments, culture media was removed completely and myotubes 
were solubilized in 0.2N NaOH.  Radioactivity of cells and TCA precipitated media 
samples was measured using scintillation counting.  Total radioactivity was calculated 
as the sum of the residual radioactivity in the myotubes plus radioactivity of all time 
points.  Protein degradation rate was directly calculated as a percentage of total [3H] 
tyrosine incorporation from the regression line of serial samples for each individual.   
RT-PCR: 
HSkMC myotubes were subjected to atrophic conditions as described above for 
24 h.  C2C12 myotubes (d4 differentiation) were infected with adenovirus expressing 
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human wtSMAD3 (ad-wtSMAD3, Vector biosystems) for 24 h, then co-infected with 
adenovirus encoding human wtFoxO3 (ad-wtFoxO3, gift of Dr. Alfred Goldberg, 
University of Harvard Medical School) for an additional 24 h.  Myotubes were washed 
twice with PBS and RNA collected using TRIzol (Ambion).  RNA was stored at -80°C 
until processing.  RNA integrity was determined by agarose gel electrophoresis.  RNA 
concentration and purity (Ab260/280) was assessed spectrophometrically using a 
NanoDrop UV-Vis spectrophometer (ThermoScientific, ND-1000).  RNA was reversed 
transcribed to cDNA (Quanta Biosciences) at a final concentration of 0.10 µg/µl.  For 
both HSkMC and C2C12 experiments, Large Ribosomal Protein (RPLPO) was used as 
an endogenous control gene and fold expression was calculated using the ΔΔCt 
method.  Custom RT-PCR primers (Table 3.1) were generated using NCBI BLAST 
algorithms (http://blast.ncbi.nlm.nih.gov/Blast.cgi) and specificity confirmed by agarose 
gel electrophoresis following conventional PCR.  All RT-PCR experiments were run with 
a standard curve of eight orders of magnitude and amplification efficiency was 
determined to be near 100%.   
Luciferase Reporter Assay   
Plasmid vectors   
Plasmids encoding wild type human FoxO1 (97), FoxO3 (79), SMAD3 (52), and 
dominant-negative SMAD3 (dnSMAD3) (16), were purchased from addgene (addgene 
plasmids13507, 10710, 11742, and 12638 respectively).  The FoxO Response Element 
reporter (FRE-luc) was a kind gift of Dr. Marco Sandri (Dulbecco Telethon Institute) 
(83).  The 5kb pGL3 wtMuRF-1 reporter (mouse) was a kind gift of Dr. Monte S. Willis 
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(University of North Carolina School of Medicine).  This reporter has previously been 
used to examine MuRF-1 promoter activity both in vivo (85) and in vitro (100).  The 
promoter region of this plasmid was confirmed by DNA sequencing and aligned against 
the human MuRF-1 promoter region using NCBI algorithms 
(http://blast.ncbi.nlm.nih.gov) to identify conserved sequences.  Site-directed 
mutagenesis (Stratagene) of two putative SMAD-binding elements (SBE, AGAC) within 
the proximal promoter region (5 and 11 bp upstream of the transcriptional start site) was 
performed to generate a 5kb mutant MuRF-1 reporter (SBE-mut).  These AGAC 
sequences were mutated to AGgg and AtcC as described by Seoane et al (88).  Both 
the 5kb wild type and 5kb SBE-mut reporters were truncated to approximately 2kb 
(digested with NheI and NdeI) and 0.25kb (digested with NheI and PstI) followed by 
blunt-end ligation (New England Biolabs).  The promoter regions of these reporters 




HEK cells were transfected with 2.0μg (including 0.25µg reporter DNA) of total 
plasmid DNA per well using FuGene 6 per manufacturer’s recommendations 
(Promega).  An eGFP plasmid was used as a transfection control and to balance total 
DNA transfection between conditions.  Experiments were performed 48 h post-
transfection.  Cells were washed twice with PBS and collected in 1x passive lysis buffer 
per manufacturer’s recommendation (Promega).  Samples were spun at 20,000 x g for 
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5 min and 20 µl of the supernatant pipetted into a white 96-well plate with 100 µl of 
substrate.  Luminescence was measured using a microplate reader (Spectramax M4).  
Luciferase values were normalized to total protein content as measured by bicinchoninic 
acid (BCA) assay (ThermoScientific) and expressed as fold relative to eGFP transfected 
cells.   
Chromatin Immunoprecipitation 
HEK cells were plated in 10cm dishes (n=6 per group) at a density of 2.0x106 
cells per dish allowed to adhere overnight, then transfected with plasmid DNA encoding 
either wt or SBE-mut 0.25kb MuRF-1 reporter and 1) eGFP, 2) wtFoxO3, 3) SMAD3, or 
4) wtFoxO3 + wtSMAD3.  Forty-eight hours after transfection, proteins were cross-
linked with chromatin using 1% formaldehyde and DNA was collected.  DNA was 
sheared by sonication to approximately 1kb fragments and antibodies against FoxO3 
(Cell Signaling #2497), SMAD3 (Cell Signaling #9523), or IgG (negative control) were 
used to immunoprecipitate DNA.  After cross-linking was reversed, RT-PCR was 
performed for the proximal region of the 0.25kb MuRF-1 reporter using primers flanking 
the FRE-SBE motif.  Using primers specific for the reporter accomplished our three-fold 
goal: 1) confirming mutagenesis eliminated SMAD3 binding within the MuRF-1 promoter 
region, 2) bypassing epigenetic modifications, such as CpG methylation that may 
prevent MuRF-1 expression in HEK cells, and 3) eliminating effects of secondary and 




C2C12 myotubes were infected with adenoviruses encoding GFP or SMAD3 
(Vector Biosystems) for 24 h.  Cells were washed twice with PBS and protein collected 
using freshly made Radio-Immunoprecipitation Assay (RIPA) buffer containing 1% NP-
40, 0.5% sodium deoxycholate, 0.1% SDS, and protease inhibitor cocktail (Roche 
Complete Mini).  Samples were vortexed continuously for 1min, rotated end-over-end 
for 30 min, then centrifuged at 12,000 x g for 10min and the pellet discarded.  Proteins 
were separated by SDS-PAGE, transferred to a polyvinylidene difluoride membrane and 
incubated with primary antibodies against FoxO3 (Cell Signaling #2497, 1:1000) or 
SMAD3 (Cell Signaling #9523, 1:5000) overnight.  Secondary antibodies were 
conjugated to horseradish peroxidase and detected using an ECL substrate (Millipore).  
Band imaging and analysis was performed using a Bio-Rad Chemi Doc XRS and Image 
Lab software.   
 
Statistics: 
Data are presented as mean ± SEM.  Statistical significance (p<0.05) was 
assessed using analysis of variance (ANOVA) followed by Tukey’s honestly significant 
difference post-hoc test when appropriate.  All analyses were performed using SPSS 
version 19.0.  
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Results: 
Starvation increases protein degradation rate and ubiquitin ligase gene 
expression in vitro 
In order to determine the response of ubiquitin ligases to muscle atrophy, we 
measured protein degradation rate and gene expression of Atrogin-1 and MuRF-1 in 
primary HSkMC myotubes in response to three atrophic stimuli.  As expected, serum 
starvation, amino acid starvation, or combined serum and amino acid starvation 
increased protein degradation rates relative to basal in a step-wise manner (Figure 
3.1A).  Likewise, atrophy stimulation increased gene expression of both Atrogin-1 
(Figure 3.1B) and MuRF-1 (Figure 3.1C) in a step-wise manner.  Gene expression of 
both Atrogin-1 and MuRF-1 was increased following 5 h of atrophy stimulation.  
Although the magnitude of the effect was decreased, gene expression of Atrogin-1 and 
MuRF-1 remained elevated following 30 h of atrophy stimulation.  Thus increased gene 
expression of Atrogin-1 and MuRF-1 is a robust and early response to atrophy 
stimulation in human skeletal muscle. 
 
SMAD3 and FoxO3 synergistically regulate transcription of Atrogin-1 and MuRF-1 
In order to determine the additive effects of SMAD3 and FoxO3 co-expression on 
transcription of ubiquitin ligases, we measured Atrogin-1 and MuRF-1 gene expression 
in C2C12 myotubes infected with ad-wtSMAD3 and/or ad-wtFoxO3.  As shown in Figure 
3.2A, wtFoxO3, but not wtSMAD3, significantly increased gene expression of Atrogin-1.  
Co-expression of wtFoxO3 and wtSMAD3 increased Atrogin-1 gene expression to a 
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greater extent than wtFoxO3 alone.  Similarly, overexpression of wtFoxO3, but not 
SMAD3, increased MuRF-1 gene expression and co-expression of wtFoxO3 and 
wtSMAD3 increased MuRF-1 gene expression to a greater extent than wtFoxO3 alone 
(Figue 3.2B).  Together, this data indicates that FoxO3 and SMAD3 synergistically 
increase gene expression of Atrogin-1 and MuRF-1. 
Examining the promoter regions of Atrogin-1 and MuRF-1 in the mouse genome 
revealed that putative SBEs occur within close proximity (9-31 bp) of consensus FREs 
within the proximal promoter regions of both genes (FRE-SBE motif).  The spacing 
between these binding sites is similar to that found for other genes coordinately 
regulated by SMAD and FoxO transcription factors (2, 33).  In the mouse Atrogin-1 
promoter region, we found three such FRE-SBE motifs within 1.5 kb upstream of the 
transcriptional start site including one located 2 bp upstream of the transcriptional start 
site.  In the human Atrogin-1 promoter region, we found one FRE-SBE motif located 22 
bp upstream of the transcriptional start site.  Using open-access software, we were 
unable to determine any highly conserved sequences between mouse and human 
genomes in the Atrogin-1 promoter region.  In the mouse MuRF-1 promoter region, we 
identified two FRE-SBE motifs within 1.5 kb of the transcriptional start site.  Aligning the 
promoter regions of the MuRF-1 gene (TRIM62) revealed the proximal 0.25kb of the 
MuRF-1 gene is highly conserved (83% homology) between mouse and human 
genomes.  Furthermore, one FRE-SBE motif, located 2 bp from the transcriptional start 
site is entirely conserved between species (Figure 3.3A).  Therefore, we focused on the 
MuRF-1 gene in order to determine the mechanistic action mediating the synergistic 
effects of SMAD3 and FoxO3. 
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In order to determine whether the synergistic effect of SMAD3 and FoxO is 
mediated by increased MuRF-1 promoter activity, we co-transfected HEK cells with a 
5kb wtMuRF-1 reporter, wtFoxO1, wtFoxO3, and/or wtSMAD3 plasmid DNA (Figure 
3.3B).  Overexpression of wtFoxO3, but not wtFoxO1, significantly increased MuRF-1 
promoter activity.  As previously reported (35, 85), overexpression of wtSMAD3  had no 
effect on MuRF-1 promoter activity.  Co-expression of wtFoxO1 + wtSMAD3 or 
wtFoxO3 + wtSMAD3 increased MuRF-1 promoter activity to a greater extent than 
wtFoxO1 or wtFoxO3 alone, indicating a synergistic effect of these transcription factors 
on MuRF-1 promoter activity.   
 
The proximal 0.25kb MuRF-1 promoter region is a major regulator of 
transcriptional activity 
In order to determine the contribution of the proximal 0.25kb promoter region and 
the FRE-SBE motif to MuRF-1 promoter activity, we created a series of reporters 
through site-directed mutagenesis (SBE-mut, AGACCAAGAC→AGggCAAtcC) and 
restriction digestion (5kb, 2kb, and 0.25kb) of the 5kb MuRF-1 luciferase reporter 
(Figure 3.3C).  These reporters were co-transfected into HEK cells and basal promoter 
activity measured (Figure 3.3D).  The wt2kb reporter retained 100% of basal 
transcriptional activity, while the wt0.25kb reporter retained 37% of basal transcriptional 
activity indicating the highly conserved proximal 0.25kb promoter region is a major 
determinant of basal MuRF-1 promoter activity.  Interestingly, the SBE-mut reporters 
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(5kb, 2kb, and 0.25kb) all retained basal promoter activity similar to their respective wild 
type reporters.   
SMAD3 augments FoxO3-induced MuRF-1 transcription in a DNA-binding 
dependent manner 
In order to determine the mechanism of the synergistic effect of FoxO3 and 
SMAD3 on MuRF-1 promoter activity, we co-transfected HEK cells with the 0.25kb 
MuRF-1 reporter (wt or SBE-mut), wtFoxO3, and/or wtSMAD3  (Figure 3.4).  As 
expected, overexpression of wtFoxO3 significantly increased MuRF-1 promoter activity 
in the wild type reporter.  However, FoxO3-induced MuRF-1 promoter activity was 
significantly attenuated in the SBE-mut reporter.  Similar results were found when 
overexpressing FoxO1 (data not shown).  Unlike the 5kb reporter, overexpression of 
wtSMAD3 alone significantly increased promoter activity in both the wild type and SBE-
mut 0.25kb reporters.  Furthermore, co-expression of wtFoxO3 and wtSMAD3 did not 
significantly increase MuRF-1 gene transcription compared to FoxO3 alone in either the 
wt or SBE-mut reporters which may be due to elimination of the upstream FRE-SBE 
motif from the MuRF-1 promoter region.  In order to confirm these results, we 
overexpressed dnSMAD3 (lacking the DNA binding region) alone or in conjunction with 
wtFoxO3.  Unlike wtSMAD3, overexpression of dnSMAD3 did not significantly increase 
MuRF-1 promoter activity, but did significantly attenuate FoxO3-induced MuRF-1 
promoter activity.  Based on these results, we hypothesized that SMAD3 binding to 
DNA augments, and is required for optimal, FoxO binding to the MuRF-1 promoter 
regions at FRE-SBE motifs. 
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In order to determine how SMAD3 affects FoxO3-DNA interactions, we 
performed chromatin immunoprecipitation (ChIP) of the 0.25kb MuRF-1 reporter.  As 
expected, SMAD3 overexpression increased SMAD3 binding within the wt (Figure 
3.5A), but not the SBE-mut (Figure 3.5B) reporter.  Interestingly, co-expression of 
wtFoxO3 and wtSMAD3 dramatically increased SMAD3 binding to DNA in both the wt 
and SBE-mut reporters (Figure3. 5A-B), suggesting that SMAD3 directly interacts with 
FoxO3 as well as SBEs within the FRE-SBE motif of the proximal promoter region.  
Overexpression of wtFoxO3, and to a lesser extent, wtSMAD3, independently increased 
FoxO3 binding within the wt reporter (Figure 3.5C).  In the SBE-mut reporter, wtFoxO3 
overexpression, but not wtSMAD3 overexpression increased FoxO3-DNA binding 
(Figure 3.5D).  Co-expression of wtFoxO3 and wtSMAD3 increased FoxO3 binding to 
DNA to a greater extent than overexpression of FoxO3 alone in both the wt and SBE-
mut reporters (Figure 3.5C-D).   
 
Overexpression of SMAD3 increases FoxO3 expression and transcriptional 
activity 
As indicated above, overexpression of dnSMAD3, which lacks the DNA binding 
region, was insufficient to induce MuRF-1 promoter activity, suggesting SMAD3-induced 
MuRF-1 gene transcription is dependent on DNA binding.  However, wtSMAD3 
overexpression was sufficient to induce MuRF-1 promoter activity in the SBE-mut 
0.25kb MuRF-1 reporter (c.f. Figure 3.4) despite the fact that SMAD binding to the FRE-
SBE motif was completely abolished in the SBE-mut reporter (c.f. Figure 3.5B).  
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Together these data suggest SMAD3-induced MuRF-1 promoter activity is dependent of 
DNA binding at sites outside of the MuRF-1 promoter region.  We therefore 
hypothesized that SMAD3-induced MuRF-1 promoter activity may be mediated by 
increased FoxO expression.  In order to determine the effects of SMAD3 on FoxO3 
expression, we infected C2C12 myotubes with increasing dosages of ad-wtSMAD3 and 
analyzed FoxO3 expression by Western blot.  As shown in Figure 3.6A, wtSMAD3 
overexpression increased FoxO3 expression in a dose-dependent manner.  
Immunoblots of HEK cells transfected with wtSMAD3 revealed similar results (images 
not shown).  However, wtSMAD3 overexpression was insufficient to induce FoxO1 or 
FoxO3 gene transcription (Figure 3.6B).   
In order to determine whether SMAD3-induced increases in FoxO protein content 
affect global FoxO-dependent gene transcription, we co-transfected 293a HEK cells 
with plasmid DNA encoding an FRE reporter and wtFoxO1, wtFoxO3, and/or wtSMAD3.  
As shown in Figure 3.6C, both wtFoxO1 and wtFoxO3 independently increased FRE-
luciferase activity.  Interestingly, although wtSMAD3 alone was insufficient to induce 
FRE-luciferase activity (1.29 fold, p=0.14), co-expression of wtFoxO1+wtSMAD3 or 





The major finding of this study is that SMAD3 synergistically augments FoxO-
induced transcription of muscle-specific ubiquitin ligases Atrogin-1 and MuRF-1 by 
increasing FoxO binding to DNA at FRE-SBE motifs within the promoter region of these 
genes.  While a few studies have found these transcription factors coordinately regulate 
gene expression (2, 33, 89), to our knowledge this is the first study to demonstrate a 
synergistic effect of these transcription factors on transcription of E3 ubiquitin ligases.  
Our data indicate that two major pathways (IGF-1-Akt-FoxO pathway and TGF-β 
signaling) regulating skeletal muscle mass converge to synergistically upregulate genes 
involved in UPS-mediated protein degradation.   
Both FoxO and SMAD transcription factors are known to increase protein 
degradation (56, 83, 85, 107).  FoxO transcription factors are known to upregulate 
transcription of both Atrogin-1 (83) and MuRF-1 (100) by binding the FRE within the 
promoter regions of these genes, but the role of SMAD3 is less clear.  Sartori (85) and 
Goodman (35) showed that SMAD3 was sufficient to induce expression of Atrogin-1 and 
induce muscle atrophy, but was insufficient to induce MuRF-1 gene transcription.  Our 
data confirm that SMAD3 overexpression is insufficient to induce 5kb MuRF-1 promoter 
activity or MuRF-1 gene expression, but demonstrate that SMAD3 augments FoxO-
induced gene expression of Atrogin-1 and MuRF-1.  Genetic knockdown of FoxO (81, 
87, 93) or SMAD (30, 38) prevents muscle atrophy in numerous chronic conditions.  
Since both Atrogin-1 and MuRF-1 are required for muscle atrophy (8), it is possible that 
disrupting the synergistic effects of FoxO and SMAD3 may preserve muscle mass 
during cachectic conditions by preventing upregulation of these ubiquitin ligases.   
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Furthermore, we have demonstrated that SMAD3 binding to the FRE-SBE motif 
is essential for optimal FoxO-induced MuRF-1 gene transcription.  Overexpression of a 
dnSMAD3 or a SBE-mut MuRF-1 reporter significantly attenuated FoxO-induced MuRF-
1 promoter activity (cf Figure 3.4).  Additionally, we demonstrated that FoxO3-DNA 
binding was dramatically reduced in the SBE-mut reporter (cf Figure 3.5C-D).  
Interestingly, SMAD3-DNA binding increases with co-expression of FoxO3 and SMAD3, 
even in the SBE-mut reporter (see Figure 5A-B), indicating that SMAD3 directly 
interacts with FoxO3.  These data suggest that FoxO and SMAD3 colocalize at FRE-
SBE motifs thus increasing stability of both transcription factors at these sites and 
augmenting each other’s transcriptional activity.  This presents a model where SMAD3 
directly interacts with both FoxO3 and DNA at the FRE-SBE motif to stabilize FoxO3 
DNA interaction thereby augmenting FoxO3-induced gene transcription.  It has 
previously been shown that FoxO and SMAD transcription factors physically associate 
(89) and FREs and SBEs lie within close proximity within promoter regions of genes 
coordinately regulated by FoxO and SMAD3 (33).  Therefore, it is possible that 
disrupting SMAD3-DNA interactions may attenuate FoxO-dependent gene transcription 
by decreasing FoxO3 affinity for FREs.  Future studies should systematically test 
whether SMAD3 inhibition is sufficient to inhibit FoxO-induced transcription of ubiquitin 
ligases and prevent muscle atrophy. 
In contrast to our data, Lokireddy et al. (56) demonstrated that myostatin 
administration increased UPS-mediated protein degradation in a SMAD3-dependent 
manner, but SMAD3 knockdown had no effect on myostatin-induced MuRF-1 gene 
expression.  It is well known that myostatin activates SMAD2 and SMAD3 (99).  
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Therefore, it is possible that SMAD2 and 3 have redundant roles in regulating MuRF-1 
gene expression.  Perhaps with knockdown of both of these transcription factors, these 
researchers may have seen a decrease in myostatin-induced MuRF-1 gene expression.  
In addition to augmenting FoxO-induced MuRF-1 gene transcription, we demonstrated 
that SMAD3 increases FoxO protein content and global FoxO-induced transcriptional 
activity.  Protein content of FoxO1 and FoxO3 has been shown to increase following 
myostatin administration in HSkMC myotubes (57), and SMAD3 inhibition may prevent 
this effect.  However, the exact mechanism of this effect is not known.  It has previously 
been suggested that SMAD3 directly induces gene transcription of FoxO1 (57).  
However, in the present study, we found no differences in FoxO1 or FoxO3 gene 
expression following SMAD3 overexpression in C2C12 myotubes, suggesting SMAD3 
increases FoxO protein content by inhibiting degradation of FoxO proteins.  In addition 
to increased protein content, SMAD3 decreases Akt-mediated phosphorylation 
(inhibition) of FoxO (4, 67, 99).  Increased protein content and decreased 
phosphorylation of FoxO would be expected to increase global FoxO-dependent 
transcriptional activity.  Using a FRE-reporter, we found that SMAD3 augmented FoxO1 
and FoxO3-dependent gene transcription, although SMAD3 overexpression alone was 
insufficient to induce FRE-luciferase activity.  
In our analysis of the Atrogin-1 and MuRF-1 promoter regions, we noted the 
FRE-SBE motif occurs frequently in the proximal promoter region of both genes.  In the 
mouse genome we noted three such motifs within the proximal 1.5kb of the Atrogin-1 
promoter region and two motifs within the proximal 1.5kb of the MuRF-1 promoter 
region.  The additional FRE-SBE motif in the Atrogin-1 gene may explain why we saw a 
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greater effect of SMAD3-FoxO3 co-expression on Atrogin-1 gene expression.  In 
addition to Atrogin-1 and MuRF-1, FoxO3 is known to regulate expression of several 
genes involved in the autophagic/lysosomal pathway (107).  It is possible that similar 
motifs are located within the promoter regions of these genes and that SMAD3 may 
directly regulate FoxO-dependent transcription of these genes.  Future studies should 
aim to determine other protein degradation genes that are coordinately regulated by 
FoxO and SMAD3 within skeletal muscle.  Additionally, SMAD3 may augment the 
transcriptional activity of other DNA binding factors that regulate muscle mass such as 
the glucocorticoid receptor and nuclear factor-Κβ (NF-Κβ).  It should be noted that our 
work primarily focused on the proximal 0.25kb of the MuRF-1 promoter region.  This 
region, as well and the FRE-SBE motif, are highly conserved between the mouse and 
human genomes, indicating the physiological significance of this work in humans.   
In summary, our data indicate that SMAD3 synergistically increases, and is 
essential for, FoxO-induced transcription of ubiquitin ligases through dual mechanisms 
(Figure 3.7).  SMAD3 increases FoxO protein content and directly interacts with DNA at 
the FRE-SBE motif within the proximal promoter region and stabilizes FoxO binding to 
enhance its transcriptional activity.  These data indicate that two major transcription 
factors regulating protein degradation converge at the proximal promoter region to 



















































Table 3.1.  Primers used for RT-PCR.  Top panel:  sequences for the mouse genome.  Bottom panel:  









































































B a sa l
5  h
3 0  h





































B a sa l
5  h
3 0  h







Figure 3.1.  Atrophy stimulation increases protein degradation rate and ubiquitin ligase gene 
expression in HSkMC myotubes.  Pooled myotubes (from four individuals) were cultured in media 
lacking serum, lacking amino acids, or lacking both serum and amino acids.  A:  Protein degradation rate 
was determined by 
3
H-tyrosine release over the course of 5 h.  Data are presented as mean ± SEM.  * 
Significantly different from basal (p<0.05).  † Significantly different from serum-starved (p<0.05).  B:  
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Figure 3.2.  FoxO3 and SMAD3 synergistically activate ubiquitin ligase gene transcription.  C2C12 
myotubes were infected with adenoviruses encoding wtSMAD3 and/or wtFoxO3, RNA collected, and RT-
PCR performed.  A:  Atrogin-1 gene expression.  B:  MuRF-1 gene expression.  Data are presented as 
mean ± SEM.  * Significantly different from basal (p<0.05).  † Significantly different from respective FoxO 
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Figure 3.3.  The proximal 0.25kb of the MuRF-1 promoter is highly conserved and accounts for 
over one-third of basal transcriptional activity. A: The 0.25kb reporter sequence is highly conserved 
between human and mouse genomes FoxO Response Element (FRE) and SMAD Binding Elements 
(SBE) of the FRE-SBE motif appear in bold.  B:  Human Embryonic Kidney (HEK293a) cells were 
transfected with plasmid DNA encoding a 5kb MuRF-1 reporter, SMAD3, wtFoxO1, and/or wtFoxO3.  
Protein was collected following 48 h of transfection and luciferase activity was measured.  * Significantly 
different from basal (p<0.05).  † Significantly different from respective FoxO overexpression only (p<0.05).  
C:  Schematic diagram of reporters used in the current study.  D:  Basal luciferase activity of the reporters 
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Figure 3.4.  SMAD3 enhances FoxO3-induced MuRF-1 promoter activity in a DNA binding 
dependent manner.  HEK 293a cells were transfected with plasmid DNA encoding a 0.25kb (wt or SBE-
mut) MuRF-1 reporter, wtFoxO3, wtSMAD3, and/or dnSMAD3.  Data are presented as mean ± SEM.  * 
Significantly different from basal (p<0.05).  † Significantly different from wt (p<0.05). § Significantly 
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Figure 3.5.  SMAD3 augments FoxO3 binding within the proximal MuRF-1 promoter region.  Human 
Embryonic Kidney (HEK293a) cells were transfected with plasmid DNA encoding the 0.25kb MuRF-1 
reporter (wt or SBE-mut), wtSMAD3 and/or wtFoxO and chromatin immunoprecipitation performed.  A-B:  
SMAD3 binding to the wt and SBE-mut reporters.  C-D:  FoxO3 binding to the wt and SBE-mut reporters.  
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Figure 3.6.  SMAD3 overexpression increases expression and transcriptional activity of FoxO3.  A:  
C2C12 myotubes were infected with increasing dosages of adenovirus encoding wtSMAD for 24 h, 
protein collected, and Western blot performed for FoxO3.  B:  Human Embryonic Kidney (HEK293a) cells 
were transfected with plasmid DNA encoding a FoxO Response Element (FRE) luciferase reporter, 
wtSMAD3, wtFoxO1, and/or wtFoxO3.  Protein was collected following 48 h of transfection and luciferase 










Figure 3.7.  Proposed dualistic mechanism of SMAD3 regulating FoxO3-induced MuRF-1 
transcription.  Cytosolic SMAD3 is phosphorylated by the Activin receptor complex upon ligand binding.  
Phosphorylated SMAD3 forms a transcriptionally active complex with SMAD4 (not shown) and gains 
nuclear access.  SMAD3 binding to the FRE-SBE motif stabilizes FoxO3 binding within the proximal 
MuRF-1 promoter region to enhance FoxO-dependent gene transcription.  Additionally, SMAD3 increases 
FoxO3 protein content, and in turn, transcriptional activity.  The combination of these pathways provides a 
feed-forward mechanism to upregulate MuRF-1 during muscle atrophy.  TGF-β: Transforming Growth  
Factor-β.  MSTN:  myostatin  
 
Chapter 4:  Supplementary data 
 
Rationale 
Obesity is accompanied by increased skeletal muscle mass (27, 69), fiber diameter 
(28), and strength (53).  Myocellular size is dictated by the balance between protein 
synthesis and degradation rates (34).  Therefore, the apparent hypertrophic phenotype 
observed in obesity must be due to differences between protein synthesis and/or 
degradation rates.  Using HSkMC, a cell culture model that retains many characteristics 
of obesity in vitro (43), we found no differences in protein synthesis or degradation rates 
between lean and severely obese (c.f. Figure 2.2, Supporting information 2.2).  
Numerous factors affecting protein synthesis and degradation, such as muscular 
overload and nutritional status/cellular milleu are different between lean and obese in 
vivo.  To determine whether excess adipose tissue may provide a training stimulus to 
increase muscle mass in obesity, we correlated lean body mass and fat mass in lean 
and obese women using dual-energy x-ray absorptiometry.  Additionally, in order to 
determine whether increased circulating free fatty acids may increase skeletal muscle 
mass, we incubated C2C12 myotubes in a high lipid environment for up to 72 h and 





Dual-energy x-ray absorptiometery (DEXA) scans from 29 lean (BMI 18.5-24.9) and 50 
obese (BMI ≥ 30.0, including 32 post-gastric bypass patients) women were analyzed for 
mineral-free lean mass and fat mass.  Subject characteristics can be found in Table 4.1.  
Scans were previously collected through ongoing studies at East Carolina University 
under IRB approval.  In order to retain anonymity of subjects, no personal identifiers 
were retained during these analyses.  Regions of interest were drawn by bisecting the 
glenohumeral joint (arms) or the neck of the femur (leg) to calculate lean mass and fat 
mass of these appendages.  In cases of extreme obesity, hemi-scans were performed 
and body composition calculated by doubling values obtained from hemi-scans. 
 
Cell culture 
Mouse skeletal muscle myoblasts (C2C12) were cultured in DMEM supplemented with 
10% fetal bovine serum and 1% penicillin/streptomycin and maintained at sub-confluent 
density prior to differentiation.  For all experiments, myoblasts were seeded into six well 
plates at a density of 2.5x105 cells per well and allowed to adhere to the plate overnight.  
Growth media was switched to low serum media (2% horse serum) to induce 
differentiation into myotubes.  All cell cultures were maintained at 37°C and 5% CO2 
and media was changed every 48 h.  Following terminal differentiation myotubes were 
cultured in media supplemented with 500μM lipid (1:1 Palmitate:Oleate) and 1mM L-
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Carnitine as a transport protein for up to 72 h.  To make 500µM lipid, 0.5 ml Palmitate 
(200mM) was dissolved in 6.7 ml warm 30% BSA.  Once dissolved, 11.8 ml of warm 
differential media was added.  Once in solution, 1 ml of 100mM Oleate was added 
(20mM) stock.  Stock lipid was diluted to a final concentration of 500µM.  For all 
experiments, control, 24 h, 48 h, and 72 h lipid treated myotubes were tested on the 
same day of differentiation. 
 
Real-time PCR 
Myotubes were washed twice with PBS, then cells were dissolved in 1 ml TRIzol 
(Ambion) and nucleotides were allowed to dissociate at room temperature for 10 min.  
Chloroform (0.2 ml) was added and tubes rotated end-over-end for 10 min then 
centrifuged at 12,000 x g for 12 min and the supernatant added to 0.5 ml isopropanol.  
RNA was pelleted by centrifugation (12,000 x g for 8 min), washed with 1.5 ml 70% 
ethanol, dissolved in 0.05 ml TE buffer and dissociated at 58°C for 10 min.  RNA was 
stored at -80°C until processing.  RNA integrity was determined by agarose gel 
electrophoresis.  RNA concentration and purity (Ab260/280) was assessed 
spectrophometrically using a NanoDrop UV-Vis spectrophometer (ThermoScientific, 
ND-1000).  RNA was reversed transcribed to cDNA (Quanta Biosciences) at a final 
concentration of 0.10 µg/µl.  Fold expression of was calculated using the ΔΔCt method.  
The geometric mean of Large Ribosomal Protein (RPLPO), GAPDH, and β-actin was 
used as an endogenous control.  Custom RT-PCR primers (Table 4.2) were generated 
using NCBI BLAST algorithms (http://blast.ncbi.nlm.nih.gov/Blast.cgi) and specificity 
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confirmed by agarose gel electrophoresis following conventional PCR.  All RT-PCR 
experiments were run with a standard curve of eight orders of magnitude and 
amplification efficiency determined to be near 100%.   
 
Luciferase assay 
C2C12 myoblasts were plated in six-well plates at a density of 2.5x105 cells per well 
and allowed to adhere overnight.  Myoblasts were transfected with plasmid DNA 
encoding a 6x SBE firefly luciferase reporter and a control pRL-Thymidine Kinase 
control reporter using Fugene 6 per manufacturer’s recommendations (Promega).  
Myotubes were switched to low serum media to induce differentiation and treated with 
lipid as described above.  Myotubes were washed twice with PBS and collected in 1x 
passive lysis buffer per manufacturer’s recommendation (Promega).  Samples were 
spun at 20,000 x g for 5 min and 20 µl of the supernatant pipetted into a white 96-well 
plate with 100 µl of substrate.  Luminescence was measured using a microplate reader 
(Spectramax M4).  Firefly luciferase (SBE reporter) was normalized to that of the control 
RL-Tk reporter and values were expressed as fold difference relative to untreated. 
 
Protein synthesis 
Lipid treated C2C12 myotubes were radiolabeled with L-[3,5-3H] tyrosine (5 µCi/ml, 
PerkinElmer Life Sciences) for 2 h, residual radioactivity was washed away, and 
proteins were precipitated with 10% TCA.  Proteins were collected in microcentrifuge 
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tubes, pelleted by centrifugation, and then dissolved in 0.1N NaOH.  Radioactivity 
incorporation was determined by scintillation counting and normalized to total protein 
content as assessed by bicinchoninic acid (BCA) assay (ThermoScientific).   
 
Protein degradation assay 
Protein degradation rate was determined by release of a radiolabeled amino acid 
as previously described (11, 107).  Terminally differentiated myotubes were 
radiolabeled with L-[3,5-3H] tyrosine (5 µCi/ml, PerkinElmer Life Sciences) for 24 h.  
Cells were thoroughly washed and radioactivity chased for 2 h using differentiation 
media supplemented with 2 mM L-tyrosine to allow degradation of short-lived proteins 
and to limit re-incorporation of the radiolabel.  Four serial media samples were collected 
over the course of 5 h.  At the end of the experiments, culture media was removed 
completely and myotubes were solubilized in 0.2N NaOH.  Radioactivity of cells and 
TCA-precipitated media samples was measured using scintillation counting.  Total 
radioactivity was calculated as the sum of the residual radioactivity in the myotubes plus 
radioactivity of all time points.  Protein degradation rate was directly calculated as a 
percentage of total [3H] tyrosine incorporation from the regression line of serial samples 

































n age ht (m) wt (kg) BMI (kg/m2) 
Lean 29 43.3 ± 3.7 1.66 ± 0.01  62.8 ± 1.00   22.8 ± 0.3 
Obese 50 46.2 ± 1.7 1.57 ± 0.01 101.8 ± 2.80*   41.6 ± 1.3* 
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Figure 4.1.  Lean body mass is increased in obesity. Dual-energy x-ray absorptiometry (DEXA) scans 
from 29 lean and 50 obese women were analyzed for lean body mass and fat mass.  Regions of interest 
were determined by bisecting the glenohumeral joint (arm) or the neck of the femur (leg).  Data are 
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Figure 4.2.  Fat mass predicts lean body mass in obesity.  A:  Total body fat mass predicts total lean 
body mass in both lean (r=-0.379, p<0.05) and obese (r=0.606, p<0.0001) women.  B:  Total body fat 
mass predicts lean mass of the legs in obese (r=0.537, p<0.0001), but not lean (r=-0.274, p=0.15), 
women.  C:  Total body fat mass predicts lean mass of the arms in obese (r=0.286, p<0.05), but not lean 
(r=-0.341, p=0.07).  D:  Fat mass of the arms predicts lean mass of the arms in obese (r=0.618, 


















ACVRIB Fwd TTGGTCTGTAGGCAGCTGGT 
Rev TTCTTCCCCCTTGTTGTCCT 
SMAD2 Fwd TTTGCTGTACTCAGTCCCCA 
Rev TGAGCTTGAGAAAGCCATCA 
SMAD3 Fwd ACAGGCGGCAGTAGATAACG 
Rev CGTAATTCATGGTGGCTGTG 
SMAD4 Fwd GGCTCTCCTTCAAAGTCGTG 
Rev GGTTGTCTCACCTGGAATTGA 































LC3B Fwd AATCACTGGCATCTTGGTGG 
Rev GAGAAGACCTTCAAGCAGCG 
ATG4B Fwd TTTCTGCCCAGAATCCAAAC 
Rev TCGGACAGGGAAGATGGA 
Gabarapl-1 Fwd TAGGAGCCTTCTCCACGATG 
Rev AGGACCACCCCTTCGAGTAT 




























FoxO3 Fwd CTTCATTCTGAACGCGCA 
Rev CTTCAAGGATAAGGGCGACA 
Atrogin-1 Fwd TCAGGGATGTGAGCTGTGAC 
Rev GACTGGACTTCTCGACTGCC 














RPLPO Fwd CCGATCTGCAGACACACACT 
Rev ACCCTGAAGTGCTCGACATC 
B-actin Fwd GCTGTATTCCCCTCCATCGTG 
Rev CACGGTTGGCCTTAGGGTTCAG 
GAPDH Fwd ACCCAGAAGACTGTGGATGG 
Rev CACATTGGGGTAGGAACAC 
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Figure 4.3.  Lipid exposure decreases expression of genes involved in protein degradation.  
C2C12 myotubes were cultured in media containing 500μM Palmitate:Oleate for up to 72 h. A:  genes 
involved in the ubiquitin-proteasome system.  B:  genes involved in the autophagic/lysosomal pathway.  
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Figure 4.4.  Prolonged lipid exposure decreases SMAD-dependent gene transcription.  Myoblasts 
were transfected with plasmid DNA encoding a 6xSBE reporter and a control renilla reporter.  Terminally 
differentiated myotubes were cultured in media containing 500μM Palmitate:Oleate for up to 72 h.  SBE-
luciferase activity was normalized to RL-Tk activity to control for transfection efficiency.  Data are 































































































Figure 4.5.  Exposure to high fat increases total protein content in C2C12 myotubes by decreasing 
basal protein synthesis rate.  Terminally differentiated myotubes were cultured in media containing 
500μM Palmitate:Oleate for up to 72 h.  A:  Protein content B: Protein synthesis rate measured over 2 h 
by 3H-tyrosine incorporation.  C:Protein degradation rate measured by 3H-tyrosine release over the 
course of 5 h.  Data are presented as mean ± SEM. * p<0.05 vs basal.  † p<0.05 vs 24 h. ‡ p<0.05 vs 
48h.
 
Chapter 5:  Global discussion 
 
Due to the common transcriptional response shared between numerous forms of 
muscle atrophy (13, 54, 82) and the impaired metabolic profile noted in skeletal muscle 
of the obese (43), the present project aimed to understand the effects of obesity on the 
transcriptional regulation of muscle protein degradation.  Severe obesity is often 
accompanied by insulin resistance (50, 77), and subsequently, decreased Akt activity 
(6).  Since Akt is a  major regulator of FoxO activity (93), we hypothesized that protein 
degradation rates would be increased in myotubes of the extremely obese both basally 
and in response to atrophic stimuli.  In order to test this hypothesis, we measured gene 
expression, flux through the major protein degradation pathways, and myotube area, in 
primary HSkMC myotubes.  This model retains many characteristics of obesity, such as 
insulin resistance (6), impaired fatty acid oxidation (43), and overexpression of atrophy-
related genes (42, 72) but eliminates confounders of in vivo research such as nutrition, 
circulating amino acid concentrations, hormonal milieu, and muscle overload that can 
be significantly different between lean and obese.  In addition to insulin resistance, 
skeletal muscle of the severely obese overexpresses myostatin (1), a TGF-β family 
member that signals through SMAD3 (56, 108).  Therefore, we further hypothesized that 
SMAD3 overexpression would augment FoxO3-induced transcription of genes involved 
in protein degradation.  We directly measured gene expression and promoter activity of 




Increased FoxO3 expression does not increase gene expression of FoxO-
inducible genes in the severely obese 
Numerous forms of muscle atrophy share a common transcriptional response to 
increase the rate of protein degradation (13, 54, 82).  Therefore, we measured gene 
expression patterns of protein degradation-related genes in myotubes from lean and 
severely obese (c.f. Figure 2.1).  Gene expression patterns of protein degradation 
genes of the UPS (Atrogin-1 and MuRF-1) and autophagic/lysosomal pathways (LC3B, 
Gabarapl-1, and ATG4B) were similar between myotubes of the lean and severely 
obese under basal and starved conditions.  In contrast to previous studies (1, 42, 72), 
we found no differences in myostatin gene expression in myotubes of the severely 
obese.  Interestingly, gene expression of the transcription factor FoxO3 was significantly 
higher in myotubes from the severely obese.  FoxO3 induces transcription of genes 
involved in both the UPS and the autophagic/lysosomal pathway (107).  Notably, FoxO3 
binds the proximal promoter regions and induces gene expression of Atrogin-1 (83) and 
MuRF-1 (100), two E3 ubiquitin ligases that are essential for muscle atrophy (8).  Since 
FoxO3 gene expression was increased in myotubes of the severely obese, it would be 
predicted that gene expression of Atrogin-1 and MuRF-1 would also be higher.  
However, we found no differences in gene expression of the FoxO3-inducible genes 
Atrogin-1, MuRF-1, LC3B, or Gabarapl-1 between myotubes of the lean and severely 




Waddell et al. (100) recently reported that the glucocorticoid receptor acts to 
synergistically increase FoxO1-induced MuRF-1 gene transcription.  Therefore, it is 
possible that increased FoxO3 expression alone is insufficient to induce expression of 
downstream genes involved in protein degradation.  Recently, a subset of genes have 
been shown to be coordinately regulated by FoxO and SMAD transcription factors (2, 
33, 89).  Therefore, we hypothesized that coordinately overexpressing FoxO3 and 
SMAD3 may synergistically increase expression of genes involved in protein 
degradation.  Given our finding of increased FoxO3 gene expression and the well-
described increase in myostatin (1, 15, 42) and SMAD3 (101) signaling in skeletal 
muscle of the severely obese in vivo, the synergistic effects of these transcription 
factors may have profound physiological relevance with regard to transcriptional 
regulation of protein degradation, especially in obesity.   
 
SMAD3 augments FoxO3-induced transcription of ubiquitin ligases 
Both FoxO3 (83, 107) and SMAD3 (35, 56, 57, 85) have been shown to 
independently increase protein degradation and cause muscle atrophy in vitro and in 
vivo.  In order to determine whether SMAD3 augments FoxO3-induced transcription of 
protein degradation genes, we co-expressed these transcription factors in C2C12 
myotubes and measured gene expression (c.f. Figure 3.2).  As expected, 
overexpression of wtFoxO3 independently increased gene expression of both Atrogin-1 
and MuRF-1.  Overexpression of wtSMAD3 was insufficient to significantly increase 
gene expression of either Atrogin-1 or MuRF-1.  Interestingly, co-expression of FoxO3 
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and SMAD3 synergistically increased gene expression of both Atrogin-1 and MuRF-1, 
indicating SMAD3 and FoxO3 synergistically regulate expression of ubiquitin ligases 
essential for protein degradation and muscle atrophy.  Contrary to previous studies (42, 
72), we found no difference in myostatin expression between myotubes of the lean and 
severely obese.  The absence of increased signaling through this pathway may explain 
the similar expression patterns of Atrogin-1 and MuRF-1 and protein degradation rates 
between myotubes of the lean and severely obese under basal conditions.  During 
numerous forms of muscle atrophy, signaling through the TGF-β pathway is increased 
(13, 19, 29, 60, 102).  We subjected myotubes to both starvation and dexamethasone to 
induce protein degradation.  Both of these treatments decreased myostatin and SMAD3 
gene expression.  Given the increased FoxO3 gene expression in skeletal muscle of the 
severely obese, atrophic stimuli that increase signaling through this pathway may cause 
dramatically increased ubiquitin ligase gene expression and UPS-mediated protein 
degradation.   
According to our data, SMAD3 augments FoxO3-induced MuRF-1 gene 
transcription via dual mechanisms:  1) increasing FoxO3 content and 2) augmenting 
FoxO3 binding to DNA within the proximal MuRF-1 promoter region (c.f. Figure 3.7).  
We discovered a highly conserved FRE-SBE motif within the proximal MuRF-1 
promoter region (c.f. Figure 3.3A).  Interestingly, three similar motifs were noted in the 
proximal 1.5 kb of the mouse Atrogin-1 promoter region.  This may explain why we 
observed a greater induction of Atrogin-1 gene expression in response to FoxO3 and 
SMAD3 co-expression.  Aligning the mouse and human Atrogin-1 promoter regions 
revealed these FRE-SBE motifs are not conserved within the human genome.  
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However, we did note one FRE-SBE motif within the proximal promoter region of 
Atrogin-1 in the human genome indicating this mechanism likely regulates Atrogin-1 
gene transcription as well.  Gomis et al. (33) previously reported that FRE and SBE 
occur within close proximity of 11 genes coordinately regulated by FoxO and SMAD3 
transcription factors, but found no consensus sequence.  Therefore, it is possible that 
FoxO and SMAD3 coordinately regulate expression of other ubiquitin ligases, and 
potentially, genes involved in the autophagic/lysosomal pathway. 
 
Flux through the major protein degradation pathways is altered in skeletal muscle 
of the severely obese 
Contrary to our original hypothesis, we found no difference in total protein 
degradation rates although flux (c.f. Figure 2.2) through the ubiquitin-proteasome 
system (UPS) and autophagic/lysosomal protein degradation pathways were 
significantly different between myotubes from the lean and severely obese (cf Figure 
2.3).  Compared to lean, the rate of flux through the autophagic/lysosomal pathway was 
significantly lower in myotubes of the severely obese under basal and starved 
conditions.  Impaired flux through the autophagic/lysosomal pathway via muscle-specific 
knockout of Atg7 results in impaired mitochondrial structure and function, increased 
ROS production, and insulin resistance in mice (106).  It is possible that decreased flux 
through this pathway may explain several metabolic abnormalities seen in obesity such 
as insulin resistance and impaired mitochondrial function both in vitro and in vivo.  While 
we did not examine these variables in the present study, future research should aim to 
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determine the cellular mechanism of autophagy deficiency-induced insulin resistance 
and its physiological significance in vivo.   
Additionally, in response to starvation, myotubes of the severely obese displayed 
a shift toward UPS-mediated protein degradation.  The differential contribution of protein 
degradation pathways in response to starvation suggests that specific proteins 
degraded during atrophy may be different between lean and the severely obese.  For 
example, contractile proteins of the thick filament are ubiquitinated by MuRF-1 and 
subsequently degraded by the UPS (18).  Recently, Atrogin-1 has been shown to 
directly interact with components of the intermediate filament as well as contractile 
proteins (58).  While we did not observe any differences in myotube area between lean 
and obese during starvation, it is possible that during muscle atrophy, the shift toward 
UPS-mediated protein degradation results in a greater loss of contractile proteins, and 
therefore, muscle strength in the severely obese.  Restoring flux through the major 
protein degradation pathways may preserve skeletal muscle metabolism and contractile 
function and thus abrogate some of the negative health consequences of obesity.   
Coordinate increases in FoxO3 expression and SMAD3 signaling may contribute 
to the increased UPS flux seen during starvation in myotubes of the severely obese.  It 
is well-described that myostatin expression (42, 59, 72) and SMAD3 phosphorylation 
(101) is increased in skeletal muscle of the obese in vivo.  Sishi et al. (91) noted 
increased MuRF-1 protein content in skeletal muscle of obese, prediabetic rats which 
may be explained by increased FoxO3 and SMAD3 acting on the proximal promoter 
region.  While we did not observe any differences in gene FoxO3 or SMAD3 gene 
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expression between myotubes of the lean and severely obese, both of these 
transcription factors undergo post-translational phosphorylation to modulate activity.  
FoxO3 activity is directly inhibited by Akt-mediated phosphorylation (93).  Given the 
insulin resistance noted in our subjects, we can postulate that FoxO3 activity would be 
higher in our severely obese myotubes since this phenotype is retained in vitro.  
Increased FoxO activity in the obese would be expected to augment residual SMAD3 
activity, resulting in increased ubiquitin ligase gene transcription.  While we did not 
observe any differences in Atrogin-1 and MuRF-1 gene expression between myotubes 
of the lean and severely obese, many genes involved in protein degradation are directly 
regulated by FoxO3 (107).  It is possible that the FRE-SBE motif is present in the 
promoter regions of other genes involved in protein degradation.   
 
Proteasome activity is higher in skeletal muscle of the severely obese 
Flux through the UPS is dependent not only on polyubiquitination of proteins, but 
also on proteasome subunit composition and, subsequently, proteasome activity.  We 
noted that proteasome capacity was higher in myotubes from the severely obese 
compared to those of lean (c.f. Figure 2.4).  Hwang et al. (45) previously reported 
differential proteasome subunit composition between skeletal muscles of the lean and 
overweight diabetics.  Additionally, numerous proteins are known to associate with and 
regulate proteolytic activity of the proteasome (21, 76).  It has previously been shown 
that expression of these genes is altered during aging-induced muscle atrophy (3).  It is 
possible that promoter regions of the genes are also affected by FoxO3 and SMAD3 in 
94 
 
a similar manner.  This mechanism may explain the increased proteasome capacity 
noted in myotubes of the severely obese. 
 
Mechanisms of muscular hypertrophy in obesity 
Myocellular size is dictated by the balance between rates of protein synthesis 
and degradation (34).   Previous reports in animals (74, 92) and humans (75) have 
shown blunted protein synthesis rates in obesity.  To date, studies regarding protein 
degradation in obesity have yielded controversial results. Diet-induced obesity 
increases expression of genes involved in protein degradation such as myostatin (59) 
and MuRF-1 (91).  Protein degradation at the whole-body level is increased in obesity 
(39, 103).  Meanwhile, skeletal muscle protein degradation is decreased in obesity (73). 
However, observational data have consistently shown that obesity is accompanied by 
increased strength (53), skeletal muscle mass (27, 69), and increased fiber diameter 
(28) compared to lean.   
Our HSkMC myotube data indicates that protein synthesis and degradation rates 
are not inherently different between skeletal muscle of the lean and severely obese.  
Therefore, it is possible that other factors such as increased muscular overload or 




Excess adipose tissue may contribute to increased muscle mass in obesity by 
increasing muscular overload 
In order to determine whether increased muscular overload due to excess 
adiposity alters muscle mass in obesity, we analyzed dual-energy absorptiometry 
(DEXA) scans from 29 lean (BMI 18.5-24.9) and 50 obese (BMI>30.0) women.  As 
expected, mineral-free lean body mass, a surrogate of muscle mass (12, 41), was 
higher in the obese (Figure 4.1).  In order to determine whether adiposity per se 
increases muscle mass by increasing muscle overload, we also analyzed lean body 
mass of the load-bearing (legs) and non-load-bearing appendages (arms).  Lean body 
mass of the legs and arms was significantly higher in the obese (Figure 4.1).  
Interestingly, total lean body mass was negatively correlated with total body fat mass in 
the lean (-0.379), but positively correlated with total body fat mass in the obese (0.606) 
(Figure 4.2A).  Additionally, lean body mass of the load-bearing appendages was 
positively correlated with total body fat mass in the obese (0.537), but not the lean 
(Figure 4.2B).  A weak correlation was noted between lean body mass of the non-load-
bearing appendages and total body fat mass in the obese (0.286), but not the lean 
(Figure 4.2C).  Interestingly, we found that a strong correlation between lean body mass 
of the non-load-bearing appendages and fat mass of the non-load-bearing appendages 
in the obese (0.618) (Figure 4.2D).  Together, these data suggest that increased fat 
mass may result in muscular hypertrophy by increasing muscular overload and 
providing a training stimulus in vivo as has been previously hypothesized (44).  
However, the magnitude of this effect on basal protein synthesis and degradation rates 
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may be difficult to measure in vivo and thus contribute to the disparate protein 
degradation results of previous studies.   
 
High fat exposure increases myocellular size by decreasing protein degradation 
rate 
In addition to adiposity, obesity is accompanied by increased circulating fatty 
acids (7).  Therefore, in order determine how a high fat cellular environment affects 
transcriptional regulation of protein degradation, we incubated C2C12 myotubes in 
media containing high fatty acids for up to 72 h.  High fat exposure significantly 
decreased, expression of genes involved in the UPS, autophagic/lysosomal pathway, 
and TGF-β signaling.  Notably, gene expression of Atrogin-1 and MuRF-1 was 
significantly down-regulated in response to high fat exposure (Figure 4.3A).  A similar 
pattern of gene expression was noted for FoxO3, although this trend failed to reach 
statistical significance.  Expression of genes involved in the autophagic/lysosomal 
pathway was more variable in their response to high fat exposure.  Gene expression of 
both LC3B and ATG4B were significantly down-regulated in response to high fat 
exposure (Figure 4.3B).  However, both Gabarapl-1 and BECN1 were unaffected by 
high fat exposure.  Interestingly, genes involved in TGF-β signaling were significantly 
down-regulated in response to high fat exposure.  Gene expression of both SMAD2 and 
SMAD3 gene expression was significantly decreased in response to high fat exposure 
(Figure 4.3C).  This pathway has recently been implicated in the development of 
skeletal muscle insulin resistance (96) and signaling through this pathway is increased 
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in obesity (59, 101).  High fat exposure induces marked insulin resistance in vitro (6).  
Downregulation of TGF-β signaling may serve to maintain insulin sensitivity during this 
treatment. 
To determine whether decreased expression of TGF-β signaling genes alters 
transcriptional response to this pathway, we expressed a SBE-luciferase plasmid in 
C2C12 and measured basal luciferase activity in response to high fat exposure.  SBE-
luciferase activity was unchanged following 24 h of high fat exposure, but decreased in 
a step-wise manner with prolonged exposure to high fat (Figure 4.4).  Our data show 
that SMAD3 is a crucial regulator of FoxO3-induced Atrogin-1 and MuRF-1 gene 
expression.  In fact, knockdown of SMAD3 transcriptional activity significantly 
attenuated FoxO3-induced MuRF-1 promoter activity.  Therefore, it is possible that 
decreased SMAD transcriptional activity may drive the decreased Atrogin-1 and MuRF-
1 gene expression noted with prolonged high fat exposure.   
Interestingly, prolonged exposure to high fat significantly increased protein 
content of C2C12 myotubes (Figure 4.5A) and this effect was independent of protein 
synthesis (Figure 4.5B).  Exposure to high fat for 24 h significantly attenuated basal 
protein degradation rate in C2C12 myotubes and this persisted through 48 h of high fat 
exposure (Figure 4.5C).  Therefore, it is possible that acute exposure to high fat, such 
as following a high fat meal or increased lipolytic activity, may reduce skeletal muscle 
protein degradation rate.  Interestingly, prolonged high fat exposure increased protein 
degradation rate in a step-wise manner; following 72 h of high fat exposure, protein 
degradation rate was not significantly different from basal.  Therefore, chronic high fat 
98 
 
exposure may produce compensatory mechanisms to increase basal protein 
degradation rate.  Since circulating free fatty acid concentration is higher in the obese 
(7, 94), this may explain why basal protein degradation rates are similar between 
skeletal muscles of the lean and severely obese.  Furthermore, repeated transient 
increases in high fat exposure, such as following multiple high fat meals, may produce 
transient post-prandial decreases in protein degradation which may in turn contribute to 
increased skeletal muscle mass observed in obesity. 
Taken together, the current project indicates that the transcriptional regulation of 
protein degradation is not inherently different between skeletal muscles of the lean and 
severely obese.  Despite the similar transcriptional regulation of protein degradation, 
myotubes of the severely obese have decreased flux through the autophagic/lysosomal 
pathway which may contribute to impaired mitochondrial function and insulin resistance 
both in vitro and in vivo.  In myotubes of the severely obese, starvation induces a shift 
toward UPS-mediated protein degradation which may result in increased degradation of 
sarcomeric proteins and, ultimately, decreased force production.   FoxO3, a major 
transcriptional regulator of both UPS and autophagic/lysosomal-mediated protein 
degradation, is overexpressed in myotubes of the severely obese.  Furthermore, FoxO3 
is synergistically activated by SMAD3 via dual mechanisms:  1) increased FoxO3 
protein content and 2) increased FoxO3 binding at conserved FRE-SBE motifs within 
the promoter region of FoxO3-inducible genes.  Coordinate activation of both these 
transcription factors likely contributes to upregulation of ubiquitin ligases during muscle 
atrophy.  Given our finding of increased FoxO3 gene expression in skeletal muscle of 
the severely obese, it is possible that atrophic stimuli that increase TGF-β signaling may 
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cause dramatically increased protein degradation and muscle atrophy in the severely 
obese.  Furthermore, exposure of myotubes to an obesogenic environment decreases 
expression of protein degradation genes and transiently decreases protein degradation 
rates.  Repeated exposure to this type of environment, combined with increased daily 
loading from increased adiposity may contribute to the increased skeletal muscle mass 
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